var title_f8_62_9184="Field management algorithm for C-spine injury";
var content_f8_62_9184=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Management of suspected cervical spine injuries in the unconscious athlete",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 647px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Athletic Injuries in the Head, Neck, and Face. Torg, JS (Ed), Lea &amp; Febiger, Philadelphia, 1982, p43.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_62_9184=[""].join("\n");
var outline_f8_62_9184=null;
var title_f8_62_9185="CNS PCM CT scans";
var content_f8_62_9185=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Head CT scans from a patient with CNS paracoccidioidomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Head CT at baseline, showing a heterogeneous and expansive hypodense lesion (diameter, 4 cm), with surrounding edema in the right frontal lobe. Note that the frontal horn of the right lateral ventriculum is deformed by compression. (B) Head CT for the same patient after 12 months of therapy with voriconazole, with significant improvement of all lesions and disappearance of edema reaction and ventricular compression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Queiroz-Telles, F, Goldani, LZ, Schlamm, HT, et al. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis 2007; 45:1462. Copyright &copy;2007 University of Chicago Press.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.journals.uchicago.edu/\">",
"      file://www.journals.uchicago.edu/",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_62_9185=[""].join("\n");
var outline_f8_62_9185=null;
var title_f8_62_9186="Large distal common iliac artery aneurysm";
var content_f8_62_9186=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Large distal common iliac artery aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large distal common iliac artery aneurym extending to the bifurcation of the external and internal iliac arteries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_62_9186=[""].join("\n");
var outline_f8_62_9186=null;
var title_f8_62_9187="Left right face positions";
var content_f8_62_9187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left and right positions in face presentations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dystocia Caused by abnormalities in Presentation, Position, or Development of the Fetus. In: Williams Obstetrics, 16th Edition, Pritchard, JA, MacDonald, PC (Eds), Appleton-Century-Crofts, New York 1980. p.808. Copyright &copy; 1980 McGraw Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_62_9187=[""].join("\n");
var outline_f8_62_9187=null;
var title_f8_62_9188="Patient information: Medicines for chronic kidney disease (The Basics)";
var content_f8_62_9188=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86002\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?32/6/32875\">",
"         Tips on taking medicines",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"UTD.htm?8/13/8412\">",
"          Medicines for chronic kidney disease",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/53/19281\">",
"         Patient information: Anemia caused by low iron (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/15/20721\">",
"         Patient information: Anemia of chronic disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/17/24850\">",
"         Patient information: Bone problems caused by kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/35/28212\">",
"         Patient information: Chronic kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/30/483\">",
"         Patient information: Dealing with side effects from medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/19/41266\">",
"         Patient information: Low-sodium diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/43/37554\">",
"         Patient information: Medicine brand and generic names (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/40/23171\">",
"         Patient information: Medicines for high blood pressure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?29/49/30484\">",
"         Patient information: Anemia caused by low iron (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/5/13398\">",
"         Patient information: Chronic kidney disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/54/33635\">",
"         Patient information: High blood pressure in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/61/39890\">",
"         Patient information: Low sodium diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/35/15921\">",
"         Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/61/32726\">",
"         Patient information: Reducing the costs of medicines (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Medicines for chronic kidney disease (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H88458230\">",
"      <span class=\"h1\">",
"       What types of medicines might people with chronic kidney disease need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with chronic kidney disease are treated with:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines that treat high blood pressure &ndash; If you have chronic kidney disease, you have a higher chance of getting serious heart problems later on. But you can help prevent heart problems by keeping your blood pressure under control. Blood pressure medicines can also help slow down your kidney disease.",
"       </li>",
"       <li>",
"        Other types of medicines &ndash; These will depend on the problems caused by your kidney disease and your other medical conditions.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It&rsquo;s important to take your medicines every day exactly as prescribed (",
"      <a class=\"graphic graphic_table graphicRef59726 \" href=\"UTD.htm?32/6/32875\">",
"       table 1",
"      </a>",
"      ). If your medicines cause unpleasant side effects or you can&rsquo;t afford them, talk to your doctor or nurse. There are often ways to deal with these problems.",
"     </p>",
"     <p>",
"      Some over-the-counter pain-relieving medicines like",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil, Motrin) or",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"       naproxen",
"      </a>",
"      (sample brand name: Aleve) can make your kidney disease worse. Talk to your doctor before you take these.",
"     </p>",
"     <p>",
"      It is a good idea to keep a list of all the medicines you take and bring it with you each time you visit any doctor. You can find an example of this kind of list at the following web site:",
"      <a class=\"external\" href=\"file://www.fda.gov/Drugs/ResourcesForYou/ucm079489.htm\">",
"       www.fda.gov/Drugs/ResourcesForYou/ucm079489.htm",
"      </a>",
"      .",
"     </p>",
"     <p>",
"      For more detailed information about your medicines, ask your doctor or nurse for information from Lexicomp, available through UpToDate. The Lexicomp hand-outs explain how to use and store your medicines. They also list possible side effects and warn you if your medicines should not be taken with certain other medicines or foods.",
"     </p>",
"     <p>",
"      Listed below are the medicines used to treat chronic kidney disease. They are also listed in the Table (",
"      <a class=\"graphic graphic_table graphicRef86675 \" href=\"UTD.htm?8/13/8412\">",
"       table 2",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H88458279\">",
"      <span class=\"h1\">",
"       Medicines that treat high blood pressure and slow kidney disease",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors can use different types of medicines to control your blood pressure. You might need to take more than 1. These medicines can also help slow down your kidney disease. Below is a list of commonly used blood pressure medicines:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        ACE inhibitors and ARBs &ndash; Angiotensin-converting enzyme inhibitors (called &ldquo;ACE inhibitors&rdquo;) and angiotensin receptor blockers (called &ldquo;ARBs&rdquo;) are often grouped together, because they work in similar ways. These medicines lower the blood pressure by relaxing the blood vessels. They also lower the pressure inside the kidneys so that the kidneys can work better.",
"        <br/>",
"        <br/>",
"        Some examples of ACE inhibitors include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?29/31/30197?source=see_link\">",
"         enalapril",
"        </a>",
"        ,",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?24/49/25365?source=see_link\">",
"         captopril",
"        </a>",
"        , and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?9/32/9734?source=see_link\">",
"         lisinopril",
"        </a>",
"        . Some examples of ARBs include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?4/50/4902?source=see_link\">",
"         candesartan",
"        </a>",
"        (brand name: Atacand) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?21/15/21749?source=see_link\">",
"         valsartan",
"        </a>",
"        (brand name: Diovan).",
"       </li>",
"       <li>",
"        Diuretics (water pills) &ndash; Diuretics lower blood pressure by helping the body get rid of extra salt and fluid. They make people urinate a lot, especially at first. If the need to urinate a lot makes it hard for you to take these medicines, work with your doctor or nurse to find a good time of the day to take them.",
"        <br/>",
"        <br/>",
"        An example of a commonly used diuretic is",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?12/14/12518?source=see_link\">",
"         furosemide",
"        </a>",
"        (brand name: Lasix).",
"       </li>",
"       <li>",
"        Other blood pressure medicines",
"        <strong>",
"        </strong>",
"        &ndash; Depending on your blood pressure and the type of kidney disease you have, your doctor might prescribe other types of blood pressure medicines, such as calcium channel blockers.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H88458296\">",
"      <span class=\"h1\">",
"       Other medicines",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor might prescribe other medicines, depending on the kinds of problems caused by your kidney disease. These might include:",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H88458311\">",
"      <span class=\"h1\">",
"       Phosphate binders",
"      </span>",
"      &nbsp;&mdash;&nbsp;Phosphate is a mineral found in many foods. Having chronic kidney disease can increase the amount of phosphate in the body. This can be harmful. To lower the amount of phosphate in the body, doctors can prescribe medicines called &ldquo;phosphate binders.&rdquo; To work, these medicines",
"      <strong>",
"       must be taken with meals and snacks",
"      </strong>",
"      . Your doctor might also recommend you eat foods that have low amounts of phosphate",
"      <em>",
"       .",
"      </em>",
"     </p>",
"     <p>",
"      Examples of phosphate binders include",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?13/17/13589?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      ,",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?7/38/7780?source=see_link\">",
"       calcium acetate",
"      </a>",
"      (sample brand name: PhosLo),",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?22/1/22548?source=see_link\">",
"       sevelamer",
"      </a>",
"      (sample brand name: Renagel), and lanthanum (brand name: Fosrenol).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H88458326\">",
"      <span class=\"h1\">",
"       Vitamin D",
"      </span>",
"      &nbsp;&mdash;&nbsp;Having chronic kidney disease can lead to having low levels of calcium in the blood. This can cause bone problems. To treat or prevent low levels of calcium in the blood, doctors can prescribe vitamin D.",
"     </p>",
"     <p>",
"      An example of a vitamin D medicine is calcitriol (brand name: Rocaltrol).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H88458341\">",
"      <span class=\"h1\">",
"       Medicines to treat anemia",
"      </span>",
"      &nbsp;&mdash;&nbsp;Anemia is the term doctors use when a person has too few red blood cells. This condition can make people feel weak or tired. It is common in people with chronic kidney disease.",
"     </p>",
"     <p>",
"      Doctors can treat anemia by giving people extra iron. They can also use medicines called erythropoietin stimulating agents (called &ldquo;ESAs&rdquo;). These include erythropoietin (brand names: Epogen, Procrit) and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?21/26/21925?source=see_link\">",
"       darbepoetin alfa",
"      </a>",
"      (brand name: Aranesp).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H88458356\">",
"      <span class=\"h1\">",
"       Sodium bicarbonate",
"      </span>",
"      &nbsp;&mdash;&nbsp;When people have chronic kidney disease, the levels of acids in their body can get abnormal. This can lead to problems like weak bones and muscles. Your doctor might prescribe a",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?4/21/4437?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      pill to help with this problem.",
"     </p>",
"     <p>",
"      People who take",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?4/21/4437?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      need to avoid eating too much salt. That&rsquo;s because sodium bicarbonate also has salt in it. Having too much salt in your body raises your blood pressure and can make your kidney disease worse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H88458371\">",
"      <span class=\"h1\">",
"       Medicines for your other medical conditions",
"      </span>",
"      &nbsp;&mdash;&nbsp;Medicines that your doctor prescribes for high blood sugar (diabetes) or high cholesterol are also important in treating your kidney disease.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H88458386\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=see_link\">",
"       Patient information: Chronic kidney disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/40/23171?source=see_link\">",
"       Patient information: Medicines for high blood pressure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=see_link\">",
"       Patient information: Dealing with side effects from medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/43/37554?source=see_link\">",
"       Patient information: Medicine brand and generic names (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/17/24850?source=see_link\">",
"       Patient information: Bone problems caused by kidney disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/19/41266?source=see_link\">",
"       Patient information: Low-sodium diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=see_link\">",
"       Patient information: Anemia caused by low iron (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/15/20721?source=see_link\">",
"       Patient information: Anemia of chronic disease (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"       Patient information: Chronic kidney disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"       Patient information: High blood pressure in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/35/15921?source=see_link\">",
"       Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"       Patient information: Low sodium diet (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=see_link\">",
"       Patient information: Anemia caused by low iron (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       Patient information: Reducing the costs of medicines (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?8/62/9188?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86002 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_62_9188=[""].join("\n");
var outline_f8_62_9188=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88458230\">",
"      What types of medicines might people with chronic kidney disease need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88458279\">",
"      Medicines that treat high blood pressure and slow kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88458296\">",
"      Other medicines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88458311\">",
"      Phosphate binders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88458326\">",
"      Vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88458341\">",
"      Medicines to treat anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88458356\">",
"      Sodium bicarbonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88458371\">",
"      Medicines for your other medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88458386\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86002\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/6/32875\">",
"      Tips on taking medicines",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_table\" href=\"UTD.htm?8/13/8412\">",
"       Medicines for chronic kidney disease",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30484?source=related_link\">",
"      Patient information: Anemia caused by low iron (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/53/19281?source=related_link\">",
"      Patient information: Anemia caused by low iron (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/15/20721?source=related_link\">",
"      Patient information: Anemia of chronic disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/17/24850?source=related_link\">",
"      Patient information: Bone problems caused by kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=related_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=related_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/19/41266?source=related_link\">",
"      Patient information: Low-sodium diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/43/37554?source=related_link\">",
"      Patient information: Medicine brand and generic names (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/40/23171?source=related_link\">",
"      Patient information: Medicines for high blood pressure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/35/15921?source=related_link\">",
"      Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_62_9189="Latent phase of labor";
var content_f8_62_9189=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Latent phase of labor",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/62/9189/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/62/9189/contributors\">",
"     Andrew J Satin, MD, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/62/9189/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/62/9189/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/62/9189/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/62/9189/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/62/9189/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal labor refers to the presence of regular uterine contractions that cause progressive dilation and effacement of the cervix and fetal descent. It is viewed in terms of its phases: latent, active, and decelerative; and its stages: first, second, and third.",
"   </p>",
"   <p>",
"    The latent phase of labor will be reviewed here. Other aspects of labor and labor abnormalities are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26742?source=see_link\">",
"       \"Mechanism of normal labor and delivery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11306?source=see_link\">",
"       \"Abnormal labor: Protraction and arrest disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=see_link\">",
"       \"Management of normal labor and delivery\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Latent phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial phase of labor is termed the latent phase. It begins at the point at which the woman perceives regular uterine contractions. These contractions gradually soften, efface, and begin to dilate the cervix. This simple definition belies a complex process not completely understood by modern science. Women have irregular contractile activity beginning in the midtrimester, with gradual alterations in the size, shape, and consistency of the cervix occurring over the remaining months of the pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This makes accurate assessment of the onset of latent phase difficult since determining exactly when a patient has entered latent phase is primarily based upon the woman's history and the judgment of the attending provider.",
"   </p>",
"   <p>",
"    The end of the latent phase occurs when the active phase begins. Precise determination of the time that latent phase ends is also problematic. The active phase is defined as the period when changes in cervical dilation accelerate to at least 1 to 2 cm per hour and the fetus descends into the birth canal. A study of the transition from latent to active phase in uncomplicated pregnancies observed that 60 percent of patients reached the latent-active phase transition by 4 cm dilation and 90 percent by 5 cm dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The average duration of latent phase in nulliparous and multiparous women is 6.4 and 4.8 hours, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prolonged latent phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prolonged latent phase is defined as &ge;20 hours for the nullipara and &ge;14 hours for the multiparous woman [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. These criteria are based upon the 95th percentile for duration of the latent phase in women with spontaneous labor. However, as discussed above, the moments of transition from false labor to latent labor to active labor cannot be determined precisely and are subjective, so determining the duration of normal and abnormal latent phase is problematic.",
"   </p>",
"   <p>",
"    If the duration of latent phase follows a normal Gaussian distribution, the overall incidence of prolonged latent phase in spontaneously laboring women should be 4 to 6 percent.",
"   </p>",
"   <p>",
"    The duration of latent phase in the induced labor is controversial, but appears to be longer than in spontaneous labor [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. In this setting, the normal biochemical and biomechanical processes occurring during spontaneous labor are distorted. Heterogeneity of induction methods, indications, and socioeconomic factors complicate any analysis of latent phase duration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;False labor and latent phase of labor initially share similar characteristics. However, the contractions and cervical changes associated with latent labor become stronger, more regular, and more frequent over time, whereas the Braxton-Hicks contractions associated with false labor diminish in frequency and intensity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR PROLONGED LATENT PHASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of the latent phase is variable and affected by internal and external factors, many of which are undefined. Women with more favorable cervices at the onset of labor appear to have a shorter latent phase [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/11\">",
"     11",
"    </a>",
"    ]. By comparison, one-half of women who enter latent phase with an unfavorable cervix go on to have a prolonged latent phase [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/4\">",
"     4",
"    </a>",
"    ]. Transverse and occiput posterior position are also risk factors for prolongation of the latent phase [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of epidural analgesia administered during the latent phase of labor on the time to and mode of delivery are controversial. Epidural advocates argue that dysfunctional labor is particularly painful and patients with dysfunctional labor are more apt to request epidural at an earlier point in their labor. This argument is supported by evidence from a randomized trial that showed that early epidural did not increase the cesarean delivery rate or prolong the duration of labor [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=see_link&amp;anchor=H12560426#H12560426\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\", section on 'Timing of epidural administration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maternal age, infant birth weight, pelvic capacity, and gestational age do not have significant effects on length of the latent phase.",
"   </p>",
"   <p>",
"    Women presenting in the latent phase of labor experienced more cesarean deliveries and active phase arrests of labor than women presenting in active labor [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/13\">",
"     13",
"    </a>",
"    ]. It is uncertain whether inherent labor abnormalities result in latent phase presentation and subsequent intervention or whether early presentation and subsequent intervention are the causes of the labor abnormalities.",
"   </p>",
"   <p>",
"    As part of prenatal care, women should be educated regarding the signs and symptoms of true labor and when to present to the hospital for labor and delivery. Hospitalized women may receive sedation and analgesia, which may lengthen the latent phase [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prolonged latent phase can be physically and emotionally exhausting for the parturient. There are few management options for spontaneously laboring women who are not tolerating latent phase:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Therapeutic rest",
"     </li>",
"     <li>",
"      Uterotonic drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Before considering these options, it is important to evaluate the pregnancy to determine whether there are obstetrical problems that should be addressed. For example, therapeutic rest is not appropriate if there are maternal or fetal indications for delivery, such as preeclampsia, abruptio placenta, chorioamnionitis, or a nonreassuring fetal heart rate pattern. Uterotonic drugs may not be appropriate if there is a fetal malpresentation or a hysterotomy scar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Therapeutic rest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic rest involves administration of parenteral analgesics to relieve the patient's discomfort and allow for progression of labor while she rests or sleeps. At many hospitals, these women are placed in an observation area for rest, rather than admitting them to labor and delivery, which has cost implications.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    administered subcutaneously (15 to 20 mg) or intramuscularly (10 mg) or other opioid analgesics may be used for therapeutic rest. Approximately 85 percent of women treated with these regimens will wake up in the active phase of labor, 10 percent will not be in labor (suggesting a diagnosis of false labor), and 5 percent will have a persistent dysfunctional pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/16\">",
"     16",
"    </a>",
"    ]. This is particularly useful in women who are tired, uncomfortable, and in early latent phase. Similarly, another common practice, after assessing the fetus, is to offer use of a sedative at home;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    (5 mg orally) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/27/32182?source=see_link\">",
"     secobarbital",
"    </a>",
"    (100 mg orally) are two commonly prescribed agents.",
"   </p>",
"   <p>",
"    There are no data on the cost effectiveness of various treatments for prolonged latent phase. The decision to observe the patient in the hospital or to send her home is based upon the provider's assessment of the patient (eg, psychological state, fatigue, parity, condition of the cervix, medical and obstetrical problems, distance from the hospital) and, to a lesser extent, bed availability. If the decision has been made to move toward delivery, regional analgesia is an option to provide therapeutic rest [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Oxytocin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Augmentation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    seems to aid progression of labor from the latent to active phase. In his classic report, Friedman concluded that oxytocin and therapeutic rest were equally efficacious and safe in correcting a protracted latent phase [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/4\">",
"     4",
"    </a>",
"    ]. For women in latent phase, the average interval between initiation of oxytocin and active labor was 3.4 hours.",
"   </p>",
"   <p>",
"    Prostaglandins, although widely used for cervical ripening and labor induction, have not been studied as a treatment for women diagnosed with prolonged latent phase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Amniotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amniotomy has been reported to shorten the latent phase of labor when used in active management of labor protocols, but most of the observed effect is probably related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    administration, which is often begun shortly after amniotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/14\">",
"     14",
"    </a>",
"    ]. The lack of efficacy of amniotomy for accelerating labor was demonstrated in a systematic review of 14 randomized trials involving 4893 women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/18\">",
"     18",
"    </a>",
"    ]. Planned amniotomy did not result in a significant reduction in the duration of the first stage of labor compared to planned 'no amniotomy' (weighted mean difference -20 minutes, 95% CI -96 to 55 minutes; five trials involving 1127 women).",
"   </p>",
"   <p>",
"    Although amniotomy is associated with an increase in maternal plasma prostaglandin concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/19\">",
"     19",
"    </a>",
"    ], the effects on the uterus and cervix are probably insufficient to result in significant augmentation of labor. Moreover, rupture of membranes diminishes the pressure of the bulging gestational sac against the cervix, which may adversely affect ripening, effacement, and dilation of the cervix [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cesarean delivery should not be performed in women in latent phase unless there is evidence of maternal or fetal deterioration necessitating prompt delivery, a contraindication to vaginal delivery, or induction of labor with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    fails. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link&amp;anchor=H30#H30\">",
"     \"Principles of labor induction\", section on 'Failed induction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CONSEQUENCES OF PROLONGED LATENT PHASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of prolonged latent phase during spontaneous labor is associated with a higher risk of cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. One possible reason for the increased rate of cesarean delivery is that prolonged latent phase may be misdiagnosed as a protraction or arrest disorder in the active phase of labor. As a result, an unwarranted cesarean delivery may be performed during false labor or latent labor.",
"   </p>",
"   <p>",
"    Friedman found that women with prolonged latent phase who eventually achieved a normal pattern of dilation and descent were not more prone to developing active phase protraction and arrest disorders than parturients with a normal latent phase, and perinatal mortality was not increased [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11306?source=see_link\">",
"     \"Abnormal labor: Protraction and arrest disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Others, however, have reported prolonged latent phase is associated with a higher risk of subsequent labor abnormalities, and that newborns are more likely to be exposed to thick meconium, have depressed five-minute Apgar scores, and require neonatal intensive care unit admission [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9189/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The latent phase is characterized by regular uterine contractions that soften, efface, and begin to dilate the cervix. The end of the latent phase occurs when the active phase begins. This is usually by 4 to 5 cm dilations. The average duration of latent phase in nulliparous and multiparous women is 6.4 and 4.8 hours, respectively. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Latent phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An abnormally long latent phase is defined as &ge;20 hours for the nullipara and &ge;14 hours for the multiparous woman. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prolonged latent phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management options for spontaneously laboring women who are not tolerating latent phase include therapeutic rest and uterotonic drugs. Cesarean delivery should not be a primary treatment for laboring women not tolerating latent phase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women who are tired and uncomfortable in early latent phase, we suggest therapeutic rest rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       Morphine",
"      </a>",
"      0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      subcutaneously enables temporary relief by providing analgesia and sedation. Approximately 85 percent of women treated with this regimen will wake up in the active phase of labor. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Therapeutic rest'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       Oxytocin",
"      </a>",
"      is appropriate for a woman who is well rested or has already received therapeutic rest. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Oxytocin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of prolonged latent phase must not be confused with a protraction or arrest disorder in the active phase of labor. Otherwise, an unwarranted cesarean delivery may be performed during false labor or latent labor. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Consequences of prolonged latent phase'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/1\">",
"      Effer SB, B&eacute;rtola RP, Vrettos A, Caldeyro-Barcia R. Quantitative study of the regularity of uterine contractile rhythm in labor. Am J Obstet Gynecol 1969; 105:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/2\">",
"      Granstr&ouml;m L, Ekman G, Ulmsten U, Malmstr&ouml;m A. Changes in the connective tissue of corpus and cervix uteri during ripening and labour in term pregnancy. Br J Obstet Gynaecol 1989; 96:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/3\">",
"      Peisner DB, Rosen MG. Transition from latent to active labor. Obstet Gynecol 1986; 68:448.",
"     </a>",
"    </li>",
"    <li>",
"     Friedman, EA. Labor: Clinical evaluation and management. Appleton-Century-Crofts, 2nd edition, New York 1978, p 73.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/5\">",
"      Friedman EA. The labor curve. Clin Perinatol 1981; 8:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/6\">",
"      Friedman EA, Niswander KR, Sachtleben MR, Nemore J. Dysfunctional labor. 8. Relative accuracy of clinical and graphic diagnostic methods. Obstet Gynecol 1969; 33:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/7\">",
"      Cheng YW, Delaney SS, Hopkins LM, Caughey AB. The association between the length of first stage of labor, mode of delivery, and perinatal outcomes in women undergoing induction of labor. Am J Obstet Gynecol 2009; 201:477.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/8\">",
"      Vahratian A, Hoffman MK, Troendle JF, Zhang J. The impact of parity on course of labor in a contemporary population. Birth 2006; 33:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/9\">",
"      Rinehart BK, Terrone DA, Hudson C, et al. Lack of utility of standard labor curves in the prediction of progression during labor induction. Am J Obstet Gynecol 2000; 182:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/10\">",
"      Harper LM, Caughey AB, Odibo AO, et al. Normal progress of induced labor. Obstet Gynecol 2012; 119:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/11\">",
"      Peisner DB, Rosen MG. Latent phase of labor in normal patients: a reassessment. Obstet Gynecol 1985; 66:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/12\">",
"      Wong CA, Scavone BM, Peaceman AM, et al. The risk of cesarean delivery with neuraxial analgesia given early versus late in labor. N Engl J Med 2005; 352:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/13\">",
"      Bailit JL, Dierker L, Blanchard MH, Mercer BM. Outcomes of women presenting in active versus latent phase of spontaneous labor. Obstet Gynecol 2005; 105:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/14\">",
"      Impey L, Hobson J, O'herlihy C. Graphic analysis of actively managed labor: prospective computation of labor progress in 500 consecutive nulliparous women in spontaneous labor at term. Am J Obstet Gynecol 2000; 183:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/15\">",
"      Boylan PC, Parisi VM. Effect of active management on latent phase labor. Am J Perinatol 1990; 7:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/16\">",
"      Koontz WL, Bishop EH. Management of the latent phase of labor. Clin Obstet Gynecol 1982; 25:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/17\">",
"      American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG committee opinion. No. 339: Analgesia and cesarean delivery rates. Obstet Gynecol 2006; 107:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/18\">",
"      Smyth RM, Alldred SK, Markham C. Amniotomy for shortening spontaneous labour. Cochrane Database Syst Rev 2007; :CD006167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/19\">",
"      Mitchell MD, Flint AP, Bibby J, et al. Rapid increases in plasma prostaglandin concentrations after vaginal examination and amniotomy. Br Med J 1977; 2:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/20\">",
"      Vincent M. Amniotomy: to do or not to do? RCM Midwives 2005; 8:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/21\">",
"      Chelmow D, Kilpatrick SJ, Laros RK Jr. Maternal and neonatal outcomes after prolonged latent phase. Obstet Gynecol 1993; 81:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/22\">",
"      Maghoma J, Buchmann EJ. Maternal and fetal risks associated with prolonged latent phase of labour. J Obstet Gynaecol 2002; 22:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9189/abstract/23\">",
"      Gharoro EP, Enabudoso EJ. Labour management: an appraisal of the role of false labour and latent phase on the delivery mode. J Obstet Gynaecol 2006; 26:534.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4473 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_62_9189=[""].join("\n");
var outline_f8_62_9189=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Latent phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prolonged latent phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RISK FACTORS FOR PROLONGED LATENT PHASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Therapeutic rest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Oxytocin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Amniotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CONSEQUENCES OF PROLONGED LATENT PHASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11306?source=related_link\">",
"      Abnormal labor: Protraction and arrest disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=related_link\">",
"      Adverse effects of neuraxial analgesia and anesthesia for obstetrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=related_link\">",
"      Management of normal labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26742?source=related_link\">",
"      Mechanism of normal labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_62_9190="Primary biliary cirrhosis VI - high power";
var content_f8_62_9190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Primary biliary cirrhosis in a 51-year-old woman with asymptomatic PBC (high power, H&amp;E)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Epithelial cells have been sloughed from one half of the bile duct. There are several eosinophils in the primarily lymphocytic infiltrate that surrounds the bile duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_62_9190=[""].join("\n");
var outline_f8_62_9190=null;
var title_f8_62_9191="Ultrasound images of two vessel cord";
var content_f8_62_9191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Ultrasound images of two vessel umbilical cord",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Normal three vessel umbilical cord. Color Doppler shows presence of two umbilical arteries, one on each side of the bladder.",
"    <br>",
"     (B) Two vessel umbilical cord. Color Doppler images show alternating single artery and vein.",
"     <br>",
"      (C) Two vessel umbilical cord. Transverse view at the level of the fetal bladder shows an artery on only one side of the fetal bladder.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Deborah Levine, MD.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_62_9191=[""].join("\n");
var outline_f8_62_9191=null;
var title_f8_62_9192="Clinical manifestations and diagnosis of ovarian cancer in pregnancy";
var content_f8_62_9192=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of ovarian cancer in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/62/9192/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/62/9192/contributors\">",
"     Carolyn D Runowicz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/62/9192/contributors\">",
"     Molly Brewer, DVM, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/62/9192/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/62/9192/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/62/9192/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/62/9192/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/62/9192/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liberal use of prenatal ultrasound for evaluation of the fetus has also resulted in increased detection of asymptomatic adnexal masses during pregnancy. Although the vast majority of these masses are benign, the possibility of cancer must be considered.",
"   </p>",
"   <p>",
"    Issues specifically pertaining to ovarian cancer diagnosed during pregnancy will be reviewed here. The management of ovarian cancer in pregnant women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4759?source=see_link\">",
"     \"Management of ovarian cancer in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis and management of ovarian cancer in nonpregnant women is also discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link\">",
"       \"Epithelial ovarian cancer: Pathology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"       \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=see_link\">",
"       \"Epithelial ovarian cancer: Initial surgical management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lifetime risk of developing ovarian cancer is 1.7 percent for women living in the United States, with the majority of cases occurring after menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/1\">",
"     1",
"    </a>",
"    ]. The probability of developing ovarian cancer during the reproductive years is low, approximately 0.01 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link\">",
"     \"Epithelial ovarian cancer: Pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In hospital-based series, 0.2 to 2 percent of pregnancies are complicated by an adnexal mass, and approximately 1 to 6 percent of these masses are malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. A review of publications on ovarian cancer during pregnancy from 1958 to 2007 included 41 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/5\">",
"     5",
"    </a>",
"    ]. The mean age at presentation was 32.6 years (range 23 to 46 years); stage at diagnosis was recorded in 39 cases: FIGO I (59 percent), FIGO II (5 percent), FIGO III (26 percent), and FIGO IV (10 percent). It is important to remember that the use of obstetrical ultrasound and cesarean delivery was much less common in the initial decades of this interval, thus there was less opportunity for incidental detection of asymptomatic adnexal masses,",
"   </p>",
"   <p>",
"    In a population-based hospital registry series of malignancies identified during pregnancy using birth records linked to hospital discharge data, ovarian cancer was the fifth most common cancer diagnosed during pregnancy, after breast, thyroid, cervical cancer and Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17207?source=see_link\">",
"     \"Breast cancer during pregnancy and lactation: Epidemiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12793?source=see_link\">",
"     \"Management of classical Hodgkin lymphoma during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=see_link&amp;anchor=H30#H30\">",
"     \"Management of early stage cervical cancer\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a separate publication using this same population-based hospital registry database, there were 87 ovarian cancers diagnosed among 9375 ovarian masses diagnosed during pregnancy (malignancy rate 0.93 percent) and 0.018 ovarian cancers diagnosed per 1000 deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/2\">",
"     2",
"    </a>",
"    ]. There was also a high proportion of tumors of low malignant potential (n = 115), reported separately, with the majority in early stage and associated with favorable maternal and neonatal outcomes.",
"   </p>",
"   <p>",
"    Cause-specific maternal mortality for all patients with a malignant ovarian tumor was low (9 of 191, 4.7 percent) at a mean of 2.43 years after diagnosis. The authors commented that the low maternal mortality rate in this series was likely due to the predominance of tumors of low malignant potential and germ cell tumors (24 of the 87 ovarian cancers). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5128?source=see_link\">",
"     \"Ovarian tumors of low malignant potential\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis can only be made by resecting the ovarian neoplasm for pathologic examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the widespread use of ultrasound, most adnexal masses remained unrecognized until cesarean delivery or until they became symptomatic, usually in the postpartum period. Now many asymptomatic masses are recognized in the first one-half of pregnancy when they are identified incidentally during an antenatal ultrasound performed for obstetrical indications [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/5\">",
"     5",
"    </a>",
"    ]. Adnexal masses that have not been diagnosed antepartum may be identified at cesarean delivery, but this is an uncommon presentation. In one retrospective series of 8330 cesarean deliveries, 68 incidental adnexal masses greater than 5 cm were identified; only one of the masses was malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other clinical presentations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonspecific symptoms &mdash; Symptoms and signs that precede the diagnosis of ovarian cancer include abdominal or back pain, constipation, abdominal swelling, and urinary symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. Since these symptoms are almost universally present in normal pregnancies, their presence is unlikely to trigger a diagnostic evaluation.",
"     </li>",
"     <li>",
"      Palpable mass &mdash; In some women, a suspicious finding, such as a palpable adnexal mass or posterior cul-de-sac nodularity, may be identified during a routine antenatal physical examination and subsequently evaluated by ultrasound.",
"     </li>",
"     <li>",
"      Acute abdominal pain &mdash; In a few patients, acute abdominal pain due to torsion of the adnexa prompts the diagnostic evaluation. Adnexal torsion occurs in about 5 percent of pregnant women with an adnexal mass (benign or malignant) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/3\">",
"       3",
"      </a>",
"      ]. In one review, adnexal masses between 6 and 8 cm in diameter had a significantly higher rate of torsion (22 percent) than either smaller or larger masses [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/9\">",
"       9",
"      </a>",
"      ]. Sixty percent of the torsions occurred between the tenth and seventeenth week of gestation; only 6 percent occurred after 20 weeks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23690?source=see_link\">",
"       \"Ovarian and fallopian tube torsion\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Elevated maternal analytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many germ cell and sex cord-stromal tumors of the ovary produce hormonal tumor markers, some of which are measured in prenatal screening programs for fetal abnormalities (eg, alpha-fetoprotein, inhibin A) (",
"    <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/10\">",
"     10",
"    </a>",
"    ]. An unexplained elevation in these maternal serum analytes, obtained while screening for neural tube defects or Down syndrome, may be the first sign of one of these tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Tumor markers in ovarian malignancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    While CA 125 is a well-described serum tumor marker for the more common epithelial ovarian cancer, it is not routinely measured during a normal pregnancy; furthermore, it can be normally elevated during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound examination, followed by magnetic resonance imaging (MRI) when the diagnosis is unclear, are the preferred modalities for imaging the pelvis in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the increasing use of prenatal ultrasound examination has resulted in increased detection of ovarian masses during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/3,11,12\">",
"     3,11,12",
"    </a>",
"    ]. Although most ultrasound-detected adnexal masses have a characteristic benign appearance, a small proportion are suspicious for malignancy. Masses that are solid or include solid elements, as well as those that are complex, or have papillary areas or septae, are more likely to be malignant. A review of adnexal masses in pregnancy noted tumor diameter greater than 10 cm and tumor growth rate greater than 3.5",
"    <span class=\"nowrap\">",
"     cm/week",
"    </span>",
"    were associated with a significantly higher risk of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/9\">",
"     9",
"    </a>",
"    ]. Suspicious neoplasms require further evaluation. The sonographic appearance of benign and malignant ovarian neoplasms is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=see_link\">",
"     \"Sonographic differentiation of benign versus malignant adnexal masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, ultrasound examination provides sufficient information to guide a decision for exploratory surgery versus conservative management, but occasionally further radiologic evaluation is required. Magnetic resonance imaging (MRI) has excellent resolution for soft tissue pathology and does not expose the patient (or fetus) to ionizing radiation; therefore, MRI is particularly useful in characterizing a pedunculated leiomyoma, red degeneration of leiomyomas, endometriomas, decidualized endometriomas and massive ovarian edema [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/13\">",
"     13",
"    </a>",
"    ]. Gadolinium-based contrast material should generally be avoided in pregnancy because fetal safety has not been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link&amp;anchor=H20#H20\">",
"     \"Diagnostic imaging procedures during pregnancy\", section on 'Iodinated contrast materials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The utility of MRI was illustrated in a review of 29 studies of pregnant women with acute abdominal or pelvic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/14\">",
"     14",
"    </a>",
"    ]. In 22 of the 29 studies, gadolinium was not administered. Correlation of clinical MRI interpretations with outcome revealed correct identification of the disease entity in all but one patient. In 22 of the 29 studies, gadolinium was not administered. Another review of MRI in the assessment of adnexal masses in pregnancy concluded that it should be considered a useful adjunct when sonography is inconclusive or insufficient to guide management [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) is avoided in pregnant women if other imaging methods can provide the needed information. The fetal ionizing radiation dose for a single CT through the pelvis is 0.035 Gy. Although fetal radiation exposure of less than 0.05 Gy has not been associated with an increased risk of abortion, congenital anomalies, growth restriction, or perinatal mortality, there remain concerns regarding a possible increase in the risk of developing childhood cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In addition, the use of iodinated contrast agents with CT carries a risk of transient suppression of the fetal thyroid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Benign neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adnexal masses detected in pregnant woman are benign. Most adnexal masses identified in pregnant women are benign simple cysts less than 5 cm in diameter. Most of these are functional ovarian cysts, either follicular or corpus luteum cysts, which occur as part of the normal physiological function of the ovary. Approximately 70 percent of all adnexal cystic masses detected in the first trimester spontaneously resolve by the early part of the second trimester, consistent with the natural history of functional cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/11\">",
"     11",
"    </a>",
"    ]. The majority of persistent adnexal masses 5 cm or greater in diameter are mature teratomas [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benign adnexal masses can be classified by their ultrasonographic appearance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign masses without complex features on ultrasound are generally",
"      <span class=\"nowrap\">",
"       physiologic/functional",
"      </span>",
"      cysts, but may be unilocular serous or mucinous cystadenoma or hydrosalpinx.",
"     </li>",
"     <li>",
"      The most common benign masses with complex features on ultrasound include hemorrhagic corpus luteum, mature teratomas, hydrosalpinx with septation, theca lutein cysts, endometriomas, leiomyomas, and multilocular cystadenomas [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/17\">",
"       17",
"      </a>",
"      ]. Theca lutein cysts (also called lutein cysts, hyperreactio luteinalis) are luteinized follicle cysts which form as a result of overstimulation from high hCG levels or hypersensitivity to hCG. Bilateral multiseptated cystic adnexal masses in a woman with gestational trophoblastic disease, multiple gestation, ovulation induction, or a pregnancy complicated by fetal hydrops are likely to represent theca lutein cysts.",
"     </li>",
"     <li>",
"      A luteoma is an uncommon solid benign lesion specific to pregnancy. It is a nonneoplastic ovarian change associated with pregnancy that can simulate a neoplasm on clinical, gross, or microscopic examination. The diagnosis should be suspected in the presence of a solid adnexal mass and maternal hirsutism or virilization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link\">",
"       \"Differential diagnosis of the adnexal mass\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of pain should suggest the possibility of heterotopic pregnancy, torsion or rupture of an ovarian neoplasm, or degeneration of a leiomyoma. (See individual topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Malignant ovarian tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelial ovarian tumors comprise about one-half of all ovarian malignancies in pregnant women, germ cell ovarian malignancies make up about one-third, and stromal tumors and a variety of other tumor types (eg, sarcomas, metastatic tumors) account for the remainder (",
"    <a class=\"graphic graphic_figure graphicRef57398 \" href=\"UTD.htm?43/44/44749\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Epithelial ovarian tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 50 percent of epithelial ovarian tumors detected in pregnancy are of low malignant potential (formerly called \"borderline\") and the other 50 percent are invasive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5128?source=see_link\">",
"     \"Ovarian tumors of low malignant potential\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epithelial ovarian tumors of low malignant potential diagnosed in pregnancy may exhibit atypical characteristics suggestive of invasive cancer. These findings include nuclear enlargement, anisocytosis, and multifocal microinvasion. For this reason, it is important that the pathologist be informed of the coexistent pregnancy and that pregnancy-associated ovarian malignancies be evaluated by a pathologist skilled in reading the pathologic findings in the context of the ongoing pregnancy.",
"   </p>",
"   <p>",
"    In one series, 8 of 10 serous neoplasms diagnosed in pregnancy had microscopic and clinical features suggesting aggressive behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/18\">",
"     18",
"    </a>",
"    ]. However, all of these features regressed postpartum in this small series, confirming that the neoplasms were of low malignant potential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Germ cell tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;About three-fourths of ovarian germ cell tumors occurring in pregnancy are dysgerminomas; endodermal sinus tumors, immature teratomas, and mixed germ cell tumors comprise the remainder [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/19\">",
"     19",
"    </a>",
"    ]. Most germ cell tumors are grossly limited to one adnexa, but lymphatic spread to pelvic or paraaortic nodes is relatively common. Dysgerminomas are bilateral in 10 to 15 percent of cases; other germ cell tumors are almost always unilateral. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Sex cord-stromal tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-half of all pregnancy-associated stromal tumors are granulosa cell tumors, one-third are Sertoli-Leydig cell tumors, and the remainder are unclassified stromal tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/20\">",
"     20",
"    </a>",
"    ]. Most of these tumors are limited to one ovary at the time of diagnosis. Prior to the routine use of prenatal ultrasound, about 20 percent of these lesions presented with intraperitoneal hemorrhage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemorrhagic shock, but this has become less common with earlier diagnosis.",
"   </p>",
"   <p>",
"    Between 10 and 15 percent of stromal tumors secrete androgens and produce virilization. Although estrogen secretion also occurs, symptoms of a hyperestrogenic state are masked by the already high estrogen concentration associated with pregnancy.",
"   </p>",
"   <p>",
"    Pregnancy-related histologic changes in these tumors include a disorderly arrangement of cells, increased edema, and unusually large numbers of lutein or Leydig cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/20\">",
"     20",
"    </a>",
"    ]. As discussed above, the pathologist should be aware of the coexistent pregnancy to ensure correct diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TUMOR MARKERS IN OVARIAN MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several of the tumor markers used to follow epithelial and nonepithelial ovarian cancers in nonpregnant women (",
"    <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"     table 1",
"    </a>",
"    ) are difficult to interpret in pregnancy because oncofetal antigens (eg, AFP, hCG, CEA, CA125) are involved in biological functions associated with fetal development, differentiation, and maturation. The levels are normally elevated during gestation and fluctuate with gestational age, or they may be abnormally elevated due to abnormal placentation or fetal abnormalities (eg, preeclampsia, Down syndrome, open neural tube defect) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Serum CA 125",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum levels of CA 125 are elevated in most cases of epithelial ovarian cancer (EOC). Unfortunately, CA 125 is also produced by normal tissues, including endometrium, and may be elevated during early gestation and immediately following delivery (",
"    <a class=\"graphic graphic_table graphicRef81621 \" href=\"UTD.htm?12/48/13069\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/10\">",
"     10",
"    </a>",
"    ]. However, CA 125 may be helpful as a tumor marker of epithelial ovarian cancer between 15 weeks of gestation and delivery, as serum values at this time are unlikely to be markedly elevated solely as a consequence of pregnancy. A CA 125 in the range of 1000 to 10,000 is likely (but not invariably) related to cancer, but values in the range of 75 to 150 could be either pregnancy-related or due to an ovarian cancer that does not demonstrate high expression of CA 125.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Alpha-fetoprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal serum levels of AFP (MSAFP) normally rise during pregnancy; serum levels are routinely assayed as part of the screen for fetal neural tube defects and Down syndrome. Although they are rare, because elevated MSAFP levels can be associated with ovarian germ cell tumors in pregnant women, we suggest evaluating the ovaries when an obstetrical examination is indicated for work-up of an abnormal maternal serum AFP screening test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High MSAFP levels are seen in some types of ovarian germ cell tumors (eg, endodermal sinus tumor, embryonal carcinoma, and mixed tumors). These levels are often &gt;1000",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    especially with pure endodermal sinus (yolk sac) tumors, which can be associated with levels &gt;10,000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. By comparison, MSAFP levels are typically &lt;500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in pregnancies complicated by neural tube defects.",
"   </p>",
"   <p>",
"    During pregnancy, AFP results are typically expressed as multiples of the median (MoM) for each gestational week because these values are easy to derive, more stable, and allow for interlaboratory variation. MSAFP levels that are above 2.0 to 2.5 MoMs are considered abnormal. The AFP levels associated with ovarian cancer typically translate into much higher MoM values than seen with neural tube defects. In one case report, a MSAFP of 26,300",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    translated into a MoM value of 24 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/23\">",
"     23",
"    </a>",
"    ]; in another, a level of 477.8 int.",
"    <span class=\"nowrap\">",
"     unit/mL",
"    </span>",
"    (370",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    translated into a MoM of 12.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/24\">",
"     24",
"    </a>",
"    ]. Some authors suggest that a MSAFP level above 9 MoM should prompt concern for germ cell tumors of either gonadal or nongonadal origin in the absence of fetal abdominal wall defects or anencephaly [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/23\">",
"     23",
"    </a>",
"    ]. In such cases, an ultrasound should be performed to look for neural tube defects",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adnexal masses. Further management depends upon the sonographic findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=see_link\">",
"     \"Prenatal screening and diagnosis of neural tube defects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27257?source=see_link\">",
"     \"Laboratory issues related to maternal serum screening for Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Lactate dehydrogenase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum lactate dehydrogenase (LDH) is elevated in the serum of women with ovarian dysgerminomas, and is a reliable marker for diagnosis and follow-up of these tumors in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/25\">",
"     25",
"    </a>",
"    ]. LDH is not elevated in normal pregnancy, although elevations can occur in some pregnancy-related disorders, such as severe preeclampsia and HELLP syndrome (Hemolysis, Elevated Liver function tests, Low Platelets) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link&amp;anchor=H21#H21\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\", section on 'Dysgerminoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"     \"HELLP syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Inhibin A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although serum inhibin A is a useful tumor marker for following the course of treatment for ovarian granulosa cell tumors in nonpregnant women, inhibin A is made in the developing placenta, and serum levels are elevated in early gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. This limits the value of inhibin A as a tumor marker during pregnancy. Like AFP, inhibin A levels may be measured as component of screening for Down syndrome so it is prudent for the sonographer to evaluate the ovaries when an ultrasound examination is indicated for evaluation of an abnormal maternal serum Down screening test. Inhibin A concentrations are, on average, twofold higher in pregnancies complicated by Down syndrome than in unaffected pregnancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=see_link&amp;anchor=H10#H10\">",
"     \"Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors\", section on 'Granulosa cell tumor'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27257?source=see_link\">",
"     \"Laboratory issues related to maternal serum screening for Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Human chorionic gonadotropin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beta subunit of human chorionic gonadotropin (hCG) is a useful marker for some germ cell neoplasms (particularly choriocarcinoma, (",
"    <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"     table 1",
"    </a>",
"    )). However, it cannot be used as a tumor marker during pregnancy due to the large physiologic increase in this hormone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=see_link\">",
"     \"Clinical manifestations and diagnosis of early pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19871155\">",
"    <span class=\"h2\">",
"     Human epididymis protein 4 (HE4)",
"    </span>",
"    &nbsp;&mdash;&nbsp;HE4 is the product of the WFDC 2 (HE4) gene that is overexpressed in ovarian cancer. Assessment of the HE4 level is approved for monitoring women with ovarian cancer for disease recurrence or progression, but not for screening. In a study of serum samples from 67 pregnant women without ovarian cancer, median HE4 values were significantly lower in pregnant women than in healthy nonpregnant premenopausal women (30.5 versus 46.6",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9192/abstract/29\">",
"     29",
"    </a>",
"    ]. The 95th percentiles for HE4 in pregnant women in the first, second, and third trimester were 49.6, 35.1, and 50.2",
"    <span class=\"nowrap\">",
"     pmol/L,",
"    </span>",
"    respectively. Levels were measured using an EIA assay kit from Fujirebio Diagnostics Inc.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In hospital-based series, 0.2 to 2 percent of pregnancies are complicated by an adnexal mass, and approximately 1 to 6 percent of these masses are malignant. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence and epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most adnexal masses in pregnant women are benign and asymptomatic and often discovered incidentally on obstetrical ultrasound examination. Symptoms and signs of ovarian cancer include abdominal or back pain, constipation, abdominal swelling, and urinary symptoms, which are also almost universally present during normal pregnancies. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An unexplained elevation in some maternal serum analytes (alpha-fetoprotein, inhibin A), obtained during screening for neural tube defects or Down syndrome, can be a sign of an ovarian germ cell tumor. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Elevated maternal analytes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasound examination, followed by magnetic resonance imaging when the diagnosis is unclear, are the preferred modalities for imaging the pelvis in pregnancy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most adnexal masses identified in pregnant women are benign simple cysts less than 5 cm in diameter. Most of these are functional ovarian cysts, either follicular or corpus luteum cysts, which occur as part of the normal physiological function of the ovary. Approximately 70 percent of all adnexal cystic masses detected in the first trimester spontaneously resolve by the early part of the second trimester, consistent with the natural history of functional cysts. The majority of persistent adnexal masses 5 cm or greater in diameter are dermoids. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Ultrasonography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epithelial ovarian tumors comprise about one-half of all ovarian malignancies in pregnant women; germ cell ovarian malignancies make up about one-third. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Malignant ovarian tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definitive diagnosis can only be made by resecting the ovarian neoplasm for pathologic examination. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several of the tumor markers used to follow epithelial and nonepithelial ovarian cancers in nonpregnant women (",
"      <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"       table 1",
"      </a>",
"      ) are difficult to interpret in pregnancy because oncofetal antigens (eg, AFP, hCG, CEA, CA125) are involved in biological functions associated with fetal development, differentiation, and maturation. The levels are normally elevated during gestation and fluctuate with gestational age, or they may be abnormally elevated due to abnormal placentation or fetal abnormalities (eg, preeclampsia, Down syndrome, open neural tube defect). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Tumor markers in ovarian malignancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     www.cancer.gov/cancertopics/factsheet/risk/brca (Accessed on May 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/2\">",
"      Leiserowitz GS, Xing G, Cress R, et al. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol 2006; 101:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/3\">",
"      Schmeler KM, Mayo-Smith WW, Peipert JF, et al. Adnexal masses in pregnancy: surgery compared with observation. Obstet Gynecol 2005; 105:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/4\">",
"      Smith LH, Dalrymple JL, Leiserowitz GS, et al. Obstetrical deliveries associated with maternal malignancy in California, 1992 through 1997. Am J Obstet Gynecol 2001; 184:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/5\">",
"      Palmer J, Vatish M, Tidy J. Epithelial ovarian cancer in pregnancy: a review of the literature. BJOG 2009; 116:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/6\">",
"      Dede M, Yenen MC, Yilmaz A, et al. Treatment of incidental adnexal masses at cesarean section: a retrospective study. Int J Gynecol Cancer 2007; 17:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/7\">",
"      Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004; 291:2705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/8\">",
"      Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007; 109:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/9\">",
"      Yen CF, Lin SL, Murk W, et al. Risk analysis of torsion and malignancy for adnexal masses during pregnancy. Fertil Steril 2009; 91:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/10\">",
"      Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 2007; 44:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/11\">",
"      Giuntoli RL 2nd, Vang RS, Bristow RE. Evaluation and management of adnexal masses during pregnancy. Clin Obstet Gynecol 2006; 49:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/12\">",
"      Machado F, Vegas C, Leon J, et al. Ovarian cancer during pregnancy: analysis of 15 cases. Gynecol Oncol 2007; 105:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/13\">",
"      Telischak NA, Yeh BM, Joe BN, et al. MRI of adnexal masses in pregnancy. AJR Am J Roentgenol 2008; 191:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/14\">",
"      Birchard KR, Brown MA, Hyslop WB, et al. MRI of acute abdominal and pelvic pain in pregnant patients. AJR Am J Roentgenol 2005; 184:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/15\">",
"      ACOG Committee on Obstetric Practice. ACOG Committee Opinion. Number 299, September 2004 (replaces No. 158, September 1995). Guidelines for diagnostic imaging during pregnancy. Obstet Gynecol 2004; 104:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/16\">",
"      Harvey EB, Boice JD Jr, Honeyman M, Flannery JT. Prenatal x-ray exposure and childhood cancer in twins. N Engl J Med 1985; 312:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/17\">",
"      Chiang G, Levine D. Imaging of adnexal masses in pregnancy. J Ultrasound Med 2004; 23:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/18\">",
"      Mooney J, Silva E, Tornos C, Gershenson D. Unusual features of serous neoplasms of low malignant potential during pregnancy. Gynecol Oncol 1997; 65:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/19\">",
"      Bakri YN, Ezzat A. Malignant germ cell tumors of the ovary. Pregnancy considerations. Eur J Obstet Gynecol Reprod Biol 2000; 90:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/20\">",
"      Young RH, Dudley AG, Scully RE. Granulosa cell, Sertoli-Leydig cell, and unclassified sex cord-stromal tumors associated with pregnancy: a clinicopathological analysis of thirty-six cases. Gynecol Oncol 1984; 18:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/21\">",
"      Frederiksen MC, Casanova L, Schink JC. An elevated maternal serum alpha-fetoprotein leading to the diagnosis of an immature teratoma. Int J Gynaecol Obstet 1991; 35:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/22\">",
"      Nawa A, Obata N, Kikkawa F, et al. Prognostic factors of patients with yolk sac tumors of the ovary. Am J Obstet Gynecol 2001; 184:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/23\">",
"      Elit L, Bocking A, Kenyon C, Natale R. An endodermal sinus tumor diagnosed in pregnancy: case report and review of the literature. Gynecol Oncol 1999; 72:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/24\">",
"      Horbelt D, Delmore J, Meisel R, et al. Mixed germ cell malignancy of the ovary concurrent with pregnancy. Obstet Gynecol 1994; 84:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/25\">",
"      Buller RE, Darrow V, Manetta A, et al. Conservative surgical management of dysgerminoma concomitant with pregnancy. Obstet Gynecol 1992; 79:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/26\">",
"      Demir SC, Evruke C, Ozgunen FT, et al. Factors that influence morbidity and mortality in severe preeclampsia, eclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome. Saudi Med J 2006; 27:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/27\">",
"      Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol 2003; 21:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/28\">",
"      Luisi S, Florio P, Reis FM, Petraglia F. Inhibins in female and male reproductive physiology: role in gametogenesis, conception, implantation and early pregnancy. Hum Reprod Update 2005; 11:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9192/abstract/29\">",
"      Moore RG, Miller MC, Eklund EE, et al. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 2012; 206:349.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3201 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_62_9192=[""].join("\n");
var outline_f8_62_9192=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Elevated maternal analytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Benign neoplasms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Malignant ovarian tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Epithelial ovarian tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Sex cord-stromal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TUMOR MARKERS IN OVARIAN MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Serum CA 125",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Alpha-fetoprotein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Lactate dehydrogenase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Inhibin A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Human chorionic gonadotropin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19871155\">",
"      Human epididymis protein 4 (HE4)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3201\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3201|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/44/44749\" title=\"figure 1\">",
"      Ovarian cancer types pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3201|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/4/24653\" title=\"table 1\">",
"      Ovarian tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/48/13069\" title=\"table 2\">",
"      Causes of an elevated CA 125",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=related_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17207?source=related_link\">",
"      Breast cancer during pregnancy and lactation: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=related_link\">",
"      Clinical manifestations and diagnosis of early pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=related_link\">",
"      Differential diagnosis of the adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=related_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/39/27257?source=related_link\">",
"      Laboratory issues related to maternal serum screening for Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12793?source=related_link\">",
"      Management of classical Hodgkin lymphoma during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/14/9449?source=related_link\">",
"      Management of early stage cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4759?source=related_link\">",
"      Management of ovarian cancer in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23690?source=related_link\">",
"      Ovarian and fallopian tube torsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=related_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5128?source=related_link\">",
"      Ovarian tumors of low malignant potential",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=related_link\">",
"      Prenatal screening and diagnosis of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/36/8778?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=related_link\">",
"      Sonographic differentiation of benign versus malignant adnexal masses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_62_9193="Hypokalemic periodic paralysis";
var content_f8_62_9193=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypokalemic periodic paralysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/62/9193/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/62/9193/contributors\">",
"     Laurie Gutmann, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/62/9193/contributors\">",
"     Robin Conwit, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/62/9193/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/62/9193/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/62/9193/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/62/9193/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/62/9193/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic paralysis is a rare neuromuscular disorder, related to a defect in muscle ion channels, characterized by episodes of painless muscle weakness, which may be precipitated by heavy exercise, fasting, or high-carbohydrate meals.",
"   </p>",
"   <p>",
"    Periodic paralysis (PP) is classified as hypokalemic when episodes occur in association with low potassium blood levels or as hyperkalemic when episodes can be induced by elevated potassium. Most cases of periodic paralysis are hereditary, usually with an autosomal dominant inheritance pattern. Acquired cases of hypokalemic PP have been described in association with hyperthyroidism. The clinical features of these disorders are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef65215 \" href=\"UTD.htm?13/14/13549\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hypokalemic PP and the periodic paralysis associated with the Andersen syndrome will be reviewed here. Other causes of periodic paralysis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/54/871?source=see_link\">",
"     \"Hyperkalemic periodic paralysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22119?source=see_link\">",
"     \"Thyrotoxic periodic paralysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemic periodic paralysis (PP) is the most common of the periodic paralyses, but is still quite rare, with an estimated prevalence of 1 in 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/1\">",
"     1",
"    </a>",
"    ]. Hypokalemic PP may be familial with autosomal dominant inheritance or may be acquired in patients with thyrotoxicosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22119?source=see_link\">",
"     \"Thyrotoxic periodic paralysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical penetrance is often incomplete, especially in women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/8\">",
"     8",
"    </a>",
"    ]. The disorder is three to four times more commonly clinically expressed in men. Approximately one-third of cases represent new mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mutation in the gene that codes for the alpha-1 subunit of the dihydropyridine-sensitive calcium channel in skeletal muscle is the most common genetic abnormality in hypokalemic PP and is found in about 70 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. A mutation in the skeletal muscle sodium channel, SCN4A, is responsible for this syndrome in other families [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Families with the latter mutation demonstrate more complete clinical penetrance, affecting men and women equally [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/15\">",
"     15",
"    </a>",
"    ]. Kindreds with hypokalemic PP who have neither of these defects have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not known how the calcium channel defect leads to episodic potassium movement into the cells and causes weakness. The following observations hint at possible aspects of an underlying mechanism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrophysiologic studies have found a decreased calcium current density as well as slower rate of activation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/10,17,18\">",
"       10,17,18",
"      </a>",
"      ]. However, calcium movement is not clearly responsible for either altered potassium fluxes or clinical symptoms.",
"     </li>",
"     <li>",
"      In addition to calcium conductance, the dihydropyridine-sensitive calcium channel has been shown to also act as a voltage sensor for excitation-contraction coupling in skeletal muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Investigators have found that hypokalemic PP is associated with a reduced sarcolemmal ATP-sensitive potassium current [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/20\">",
"       20",
"      </a>",
"      ]. This finding can be tied to the clinical manifestations of hypokalemic PP, but the relationship with the primary calcium channel defect is unclear. The investigators suggest the possibility of a secondary, calcium-sensitive channelopathy.",
"     </li>",
"     <li>",
"      In vitro studies showed that blocking the dihydropyridine-sensitive calcium channel in muscle fibers from patients with hypokalemic PP does not prevent insulin-induced membrane depolarization [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/21\">",
"       21",
"      </a>",
"      ]. This is also consistent with a secondary channelopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism of paralysis in patients with sodium channel defect is better understood. Mutant sodium channels produce an anomalous gating pore current that may cause aberrant depolarization during attacks of weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all the periodic paralyses, attacks occur suddenly with generalized weakness. Consciousness is preserved and bulbar and respiratory muscles are only mildly affected, if at all.",
"   </p>",
"   <p>",
"    In hypokalemic PP, attacks begin in late childhood or teenage years. These attacks vary in frequency and duration. Intervals of weeks to months are common, but some patients experience several attacks per week. Attacks typically last several hours, but the duration can range from minutes to days. Attacks may be triggered by rest after vigorous exercise, stress, or a high-carbohydrate meal, often after a delay of several hours. These events are often associated with an increased release of epinephrine or insulin, both of which cause movement of potassium into cells and low potassium blood levels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurologic examination during an attack demonstrates weakness, usually affecting proximal more than distal muscles, and the legs more than the arms; hyporeflexia or areflexia is typical. Between attacks, the neurologic examination is usually normal; the myotonia typical of hyperkalemic PP is not a feature of hypokalemic PP. Some patients experience a milder degree of weakness between attacks that fluctuates and improves with mild exercise.",
"   </p>",
"   <p>",
"    The mean plasma potassium concentration during the attack in one series was 2.4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/9\">",
"     9",
"    </a>",
"    ]. Levels can be as low as 1.5; however, concentrations less than 2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    should suggest a secondary cause of hypokalemic paralysis, such as that seen in some cases of severe hypokalemia due to distal renal tubular acidosis. Between attacks, potassium levels normalize in hypokalemic PP, but remain low in secondary hypokalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac arrhythmias, such as tachycardia, atrial fibrillation, paroxysmal supraventricular tachycardia, or ventricular fibrillation are not common but have been reported during attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/3\">",
"     3",
"    </a>",
"    ]. During attacks, the ECG may otherwise show findings consistent with hypokalemia, including depression of the ST segment, decrease in the amplitude of the T wave, and an increase in the amplitude of U waves. (",
"    <a class=\"graphic graphic_waveform graphicRef73888 \" href=\"UTD.htm?18/38/19043\">",
"     waveform 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=see_link&amp;anchor=H12#H12\">",
"     \"ECG tutorial: Miscellaneous diagnoses\", section on 'Hypokalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A progressive proximal myopathy ultimately develops in most patients with hypokalemic PP [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/24\">",
"     24",
"    </a>",
"    ]. This becomes clinically manifest in most individuals after the age of 50 years, as attacks of paralysis wane. Evidence of muscle disease may be evident on muscle biopsy or computed tomography scans several years before it manifests clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Clinically and pathologically, the myopathy is most profound in muscles of the pelvic girdle as well as the proximal upper and lower extremities. The severity of the myopathy is variable; patients may be only mildly affected or severely disabled. While a correlation between the severity of the myopathy and the number of paralytic attacks is suggested by some, there is little evidence to support this, and in at least one family, this association was not found [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/24,26-28\">",
"     24,26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some suggest that hypokalemic PP associated with sodium channel abnormalities is phenotypically as well as genetically distinct from the calcium channel disorder, with more prominent myalgias, a younger age of onset, shorter duration of attacks, and less severe myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/9,15\">",
"     9,15",
"    </a>",
"    ]. Also, tubular aggregates rather than vacuoles are more frequently observed on muscle biopsy and worsening rather than improvement of symptoms with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    occur in some, but not all, patients with the sodium channel variant of hypokalemic PP. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Preventive treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemic PP must be distinguished from other causes of periodic paralysis, which are discussed separately. In particular, paralytic attacks in thyrotoxicosis and in the Andersen syndrome can be associated with hypokalemia and must be explicitly excluded because treatment and preventive strategies are different in these disorders. The distinguishing clinical features of these disorders are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef65215 \" href=\"UTD.htm?13/14/13549\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Andersen syndrome'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/54/871?source=see_link\">",
"     \"Hyperkalemic periodic paralysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=see_link&amp;anchor=H17#H17\">",
"     \"Neurologic manifestations of hyperthyroidism and Graves' disease\", section on 'Thyrotoxic periodic paralysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other disorders that can cause intermittent muscle weakness include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myasthenia gravis. Weakness in myasthenia gravis typically occurs predictably in the setting of milder degrees of exertion, does not occur in \"attacks\" as does periodic paralysis, and often involves bulbar and extraocular muscles, which are rarely if ever affected in hypokalemic PP. In contrast to periodic paralysis, when profound weakness occurs in a myasthenic crisis, respiratory muscle involvement is common. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link\">",
"       \"Clinical manifestations of myasthenia gravis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metabolic myopathies. Patients with a metabolic myopathy typically complain of exercise intolerance, with myalgias and muscle fatiguability, rather than attacks of weakness. Myoglobinuria may accompany or follow more severe symptoms (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=see_link\">",
"       \"Approach to the metabolic myopathies\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Secondary hypokalemia. Episodic weakness may be seen in association with severe hypokalemia due to renal, gastrointestinal, or other causes [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/29-34\">",
"       29-34",
"      </a>",
"      ]. There is typically clinical or laboratory evidence of the underlying systemic disease, and hypokalemia persists between attacks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link\">",
"       \"Clinical manifestations and treatment of hypokalemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link\">",
"       \"Causes of hypokalemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a first attack of quadriparesis, other diagnoses such as Guillain Barr&eacute; syndrome, acute myelopathy (eg, transverse myelitis), myasthenic crisis, tick paralysis, and botulism may be considered initially. However, the finding of hypokalemia generally alerts the clinician to the diagnosis of hypokalemic PP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When there is an established family history of hypokalemic PP, episodes of periodic paralysis often require no further diagnostic evaluation. Otherwise, the diagnosis of hypokalemic PP is suggested by documentation of hypokalemia during a typical attack of weakness. Even when this is demonstrated, other testing is required to rule out alternative diagnoses.",
"   </p>",
"   <p>",
"    When patients are evaluated after or between attacks, the diagnosis may be difficult. Further diagnostic options include genetic tests, provocative testing and electromyography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Initial laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;During an acute attack, measurement of serum potassium is required, both for diagnosis and to guide treatment. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Acute treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other testing is also required to rule out alternative diagnoses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperthyroidism should be excluded with laboratory testing: T3, T4, and TSH levels. In the acute setting, findings of tachycardia and hypophosphatemia can raise suspicion of this disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=see_link&amp;anchor=H17#H17\">",
"       \"Neurologic manifestations of hyperthyroidism and Graves' disease\", section on 'Thyrotoxic periodic paralysis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An electrocardiogram (ECG) should be performed to identify a prolonged QT or QU interval suggestive of Andersen syndrome (",
"      <a class=\"graphic graphic_waveform graphicRef77018 \" href=\"UTD.htm?26/24/27008\">",
"       waveform 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Andersen syndrome'",
"      </a>",
"      below.) During an attack of hypokalemic PP, the ECG may otherwise show findings consistent with hypokalemia, including depression of the ST segment, decrease in the amplitude of the T wave, and an increase in the amplitude of U waves. (",
"      <a class=\"graphic graphic_waveform graphicRef73888 \" href=\"UTD.htm?18/38/19043\">",
"       waveform 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=see_link&amp;anchor=H12#H12\">",
"       \"ECG tutorial: Miscellaneous diagnoses\", section on 'Hypokalemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An arterial blood gas, blood urea nitrogen, creatinine, and other electrolytes (phosphate, calcium, and magnesium) should be measured during an acute attack.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one case series, a metabolic acidosis or alkalosis was found in all cases with secondary hypokalemia and in none of the patients with periodic paralysis [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypophosphatemia can cause acute paralysis in patients with diabetic ketoacidosis who may also have hypokalemia [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study, the following findings during an acute attack were reliable tests to distinguish hypokalemic PP from secondary hypokalemic paralysis: a low urine potassium-creatinine concentration ratio (&lt;22",
"      <span class=\"nowrap\">",
"       meq/g",
"      </span>",
"      or &lt;2.5",
"      <span class=\"nowrap\">",
"       meq/mmol);",
"      </span>",
"      and a low transtubular potassium concentration gradient (&lt;3.0) as calculated from (urine",
"      <span class=\"nowrap\">",
"       K/plasma",
"      </span>",
"      K) &divide; (urine",
"      <span class=\"nowrap\">",
"       osmolality/plasma",
"      </span>",
"      osmolality) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/9/9366?source=see_link&amp;anchor=H60966904#H60966904\">",
"       \"Evaluation of the patient with hypokalemia\", section on 'Severe hypokalemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal plasma potassium levels between attacks help distinguish primary hypokalemic PP from other secondary causes of hypokalemic paralysis, such as distal renal tubular acidosis (RTA) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"       \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The value of these tests is illustrated in case series. Diagnostic evaluation in 34 patients with episodic weakness from Thailand determined that 11 had thyrotoxic periodic paralysis, 8 had distal RTA, and 15 had hypokalemic PP [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/38\">",
"     38",
"    </a>",
"    ]. Hypokalemic PP occurred without a known family history in two-thirds of cases. Among those with RTA, a metabolic acidosis was noted in only two patients. Only subtle clinical signs of hyperthyroidism were observed in 4 of 11 patients with hyperthyroidism. In a larger case series of 97 patients with an initial diagnosis of hypokalemic PP in the emergency department, 31 had hypokalemic PP, 39 had thyrotoxic periodic paralysis, and 24 had secondary hypokalemia (RTA, aldosteronism, Bartter syndrome, others) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/35\">",
"     35",
"    </a>",
"    ]. Only two patients with hypokalemic PP had a family history in this series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is possible to test for many but not all of the mutations that underlie hypokalemic PP. When genetic testing is negative, further testing with provocative testing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electromyography may help establish the diagnosis of hypokalemic PP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Provocative testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Provocative testing can be employed, when genetic testing fails to identify an underlying mutation. Careful monitoring, usually in an inpatient setting, is recommended for all forms of provocative testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Precipitating an attack of hypokalemic PP with an oral glucose load (2",
"      <span class=\"nowrap\">",
"       gm/kg)",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      insulin administration (10 units subcutaneously) can be risky [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/39\">",
"       39",
"      </a>",
"      ]. This should be done in an inpatient setting with continuous cardiac monitoring and with availability of emergency resuscitative measures in case cardiac arrhythmias occur. Preexisting cardiac or renal disease precludes such testing and should be excluded prior to this test.",
"     </li>",
"     <li>",
"      Exercise, such as 30 minutes of running on the treadmill, may provide a safer alternative to glucose or insulin administration. A positive response, weakness with accompanying hypokalemia, is more helpful than a negative response, because some patients do not have reliably-induced attacks.",
"     </li>",
"     <li>",
"      Both hypokalemic PP and hyperkalemic PP can be induced with ACTH. In one study, in five patients with suspected hypokalemic PP, ACTH (80 to 100 IU IM) was administered in the evening [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/40\">",
"       40",
"      </a>",
"      ]. Muscle strength was assessed in the hand with a dynamometer at baseline and every one to two hours, along with measurement of serum potassium. Weakness was observed along with a fall in serum potassium to &lt;2.5",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      13 to 27 hours after ACTH administration in four patients. Significant side effects did not occur, but hospitalization and careful monitoring is recommended for provocative testing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;During an attack, electromyography (EMG) may show decreased amplitude of the compound muscle action potential (CMAP), with reduced motor unit recruitment or electrical silence, depending on the severity of weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/10,39\">",
"     10,39",
"    </a>",
"    ]. Other findings more variably described include increased insertional activity, increased polyphasic motor unit potentials, and reduced muscle fiber conduction velocity.",
"   </p>",
"   <p>",
"    An EMG technique that may be used to help confirm the diagnosis between attacks is the \"exercise test.\" CMAPs following a single supramaximal electrical stimulus are recorded at rest and every one to two minutes following two to five minutes of exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/41\">",
"     41",
"    </a>",
"    ]. Exercise consists of maximal contraction of a muscle (biceps or anterior tibialis) for two to five minutes with three to four-second rest periods every 15 seconds. A gradual reduction of over 40 percent in the evoked motor amplitude after 30 to 40 minutes is compatible with a diagnosis of periodic paralysis but is not specific to hypokalemic PP. This test had a sensitivity of 71 percent in a case series of patients with periodic paralysis (either hypokalemic PP, hyperkalemic PP, or thyrotoxic PP) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/41\">",
"     41",
"    </a>",
"    ]. The sensitivity declines when attacks have not been recent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/42\">",
"     42",
"    </a>",
"    ]. Other investigators have found that the test is also highly specific (97 to 98 percent) for muscle ion channel disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report suggests that the EMG exercise test can discriminate between types of periodic paralysis. These investigators found that an initial increase in CMAP followed by a delayed decrease was seen in five of six patients with hyperkalemic PP after short-duration exercise (10 to 12 seconds) and only 1 of 13 patients with hypokalemic PP associated with a calcium channel defect [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/44\">",
"     44",
"    </a>",
"    ]. Of the two patients with the sodium channel variant of hypokalemic PP, one had this finding.",
"   </p>",
"   <p>",
"    The presence of myotonia on EMG strongly suggests the alternative diagnosis of hyperkalemic PP. This finding is seen in up to 80 percent of patients with hyperkalemic PP, in no patients with hypokalemic PP associated with the calcium channel defect, and rarely in patients with the sodium channel variant of hypokalemic PP or without an identified mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/9,45\">",
"     9,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/54/871?source=see_link\">",
"     \"Hyperkalemic periodic paralysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When myasthenia gravis is considered, other techniques such as repetitive nerve stimulation and single-fiber EMG are useful tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link\">",
"     \"Diagnosis of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A muscle biopsy is not usually performed in the diagnosis of periodic paralysis. Vacuolar changes, representing reduplication of the sarcoplasmic reticulum and transverse tubules, are nonspecific findings common to all periodic paralyses [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/10\">",
"     10",
"    </a>",
"    ]. Tubular aggregates are less often seen, but may be more common in the sodium channel mutation variant of hypokalemic PP and in the Andersen syndrome.",
"   </p>",
"   <p>",
"    More significant myopathic changes on muscle biopsy are described in patients who develop the progressive myopathy, usually several years after their initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ACUTE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral administration of 60 to 120 meq of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    , given incrementally, usually aborts acute attacks of hypokalemic periodic paralysis. Recovery may take minutes to hours. Important caveats of acute treatment include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of hypokalemia must be confirmed prior to therapy, since potassium administration can worsen episodes due to hyperkalemic PP [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/2,46\">",
"       2,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Potassium administration during an acute episode may lead to posttreatment hyperkalemia as potassium moves back out of the cells [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/3,5,34,47-49\">",
"       3,5,34,47-49",
"      </a>",
"      ]. Treatment should therefore be administered incrementally and posttreatment potassium levels should be monitored for 24 hours.",
"     </li>",
"     <li>",
"      Potassium should not be administered in solutions containing dextrose, as patients have an exaggerated insulin response to carbohydrate loads [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/50,51\">",
"       50,51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac monitoring is recommended during treatment and posttreatment monitoring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A suggested protocol is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    30 meq orally every 30 minutes until serum potassium normalizes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/10\">",
"     10",
"    </a>",
"    ]. However, some recommend slower rates of administration (10 mEq per hour), to minimize rebound hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Milder attacks can be aborted by low level exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PREVENTIVE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic interventions that may be effective for preventing attacks include a low-carbohydrate diet and refraining from vigorous exercise. When attacks continue to be disabling, prophylactic treatment is indicated to avoid morbidity, even mortality, which can be associated with hospitalization and acute treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/52\">",
"     52",
"    </a>",
"    ]. Medications, symptomatic potassium supplementation, potassium-sparing diuretics, and carbonic anhydrase inhibitors are used when lifestyle changes are not sufficiently effective [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/3,53,54\">",
"     3,53,54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The carbonic anhydrase inhibitor dichlorphenamide (50 mg twice daily) was demonstrated to be more effective than placebo in reducing attack frequency in the only clinical trial demonstrating a benefit for treatment in periodic paralysis [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]. Dichlorphenamide is no longer available in the United States.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       Acetazolamide",
"      </a>",
"      (250 mg twice daily) is also commonly reported to be effective in reducing attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/1,10,57\">",
"       1,10,57",
"      </a>",
"      ]. The subset of patients who experience mild, fluctuating weakness between attacks, reportedly find acetazolamide treatment helpful [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/1\">",
"       1",
"      </a>",
"      ]. However, one retrospective study found that only half of patients respond to acetazolamide therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/58\">",
"       58",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In one case report, two twin boys with attacks refractory to a combined acetazolamide and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      regimen were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      75 to 100 mg twice daily [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/59\">",
"       59",
"      </a>",
"      ]. While attack frequency increased, the severity of individual attacks was decreased, resulting in fewer emergency room visits and an overall improved quality of life.",
"      <br/>",
"      <br/>",
"      The mechanism whereby carbonic anhydrase inhibitors are effective in hypokalemic PP is not clear, but appears to be independent of carbonic anhydrase inhibition [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. Studies in animal models suggest that these agents trigger calcium-activated potassium channels on skeletal muscle. Side effects such as malaise and fatigue limit tolerability in some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/55\">",
"       55",
"      </a>",
"      ]. Kidney stones are a potential complication of treatment with these agents.",
"     </li>",
"     <li>",
"      A potassium-sparing diuretic, either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      (100 mg daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/60/43973?source=see_link\">",
"       triamterene",
"      </a>",
"      (150 mg daily), can be effective as monotherapy or as a supplement to carbonic anhydrase inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/10\">",
"       10",
"      </a>",
"      ]. Potassium supplementation should be avoided in these patients.",
"     </li>",
"     <li>",
"      The efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      240 mg daily was studied for three weeks in nine patients using a randomized, cross-over design [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/57\">",
"       57",
"      </a>",
"      ]. While verapamil treatment was not associated with a reduced frequency of events in the group as a whole, two patients experienced significant reduction of events on verapamil.",
"     </li>",
"     <li>",
"      Pinacidil, a potassium channel opener, (not available in the United States) appeared to improve strength during episodes of induced hyperglycemia compared with placebo in four patients with hypokalemic PP [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/56,62\">",
"       56,62",
"      </a>",
"      ]. However, no clinical paralytic attacks were provoked in either the placebo or pinacidil-treated patients in this study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of these interventions may vary with the specific mutation, but this requires further analysis. In one retrospective review of 74 patients, those with mutations in CACNA1S were more likely to respond to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    compared to those with SCN4A mutation (56 versus 16 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/58\">",
"     58",
"    </a>",
"    ]. In other reports, some family members with a specific mutation in the calcium channel had marked improvement with treatment with potassium-sparing diuretics after failing to respond to acetazolamide [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Acetazolamide has been reported to exacerbate symptoms in some families with mutations in the sodium channel, but not in others [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/15,65\">",
"     15,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no known treatment for the late-onset myopathy in hypokalemic PP. While some believe that limiting attacks of periodic paralysis ameliorates the subsequent myopathy, this is unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/24,26,27\">",
"     24,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association between malignant hyperthermia and hypokalemia is uncertain, but has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/52\">",
"     52",
"    </a>",
"    ], suggesting caution be used when certain inhalational anesthetic agents or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    are used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link\">",
"     \"Susceptibility to malignant hyperthermia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ANDERSEN SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rare disorder, estimated at one-tenth the prevalence of hypokalemic periodic paralysis, the Andersen-Tawil or Andersen syndrome is clinically and genetically distinct from other periodic paralyses. It is manifest by a triad of periodic paralysis, ventricular dysrhythmias, and dysmorphic features (short stature, hypertelorism, clinodactyly, micrognathia) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. A prolonged QT interval on electrocardiogram (ECG) is also a feature of this disorder (",
"    <a class=\"graphic graphic_waveform graphicRef77018 \" href=\"UTD.htm?26/24/27008\">",
"     waveform 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical features of congenital long QT syndrome\", section on 'Andersen syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potassium may be low, normal, or high during paralytic attacks, which first manifest during the first or second decade of life [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/10,66-68\">",
"     10,66-68",
"    </a>",
"    ]. Low potassium levels are noted somewhat more frequently. Similar to other syndromes, paralytic attacks are commonly precipitated by rest after exercise. However, a dietary trigger is rarely identified. Provocative challenges to induce hypokalemia or hyperkalemia should not be performed in these patients because of the risk of cardiac arrhythmias.",
"   </p>",
"   <p>",
"    A mutation in the gene encoding Kir2.1, an inward rectifier potassium channel expressed in cardiac and skeletal muscle, is identified in approximately two-thirds of patients. Nonpenetrance occurs in about 20 percent of individuals who inherit the mutation. Incomplete penetrance and marked intrafamilial phenotypic variation is also common; isolated features, particularly a long QT interval, may be manifest in family members who exhibit no other features of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/67,69\">",
"     67,69",
"    </a>",
"    ]. The function of Kir2.1 is better established in cardiac than skeletal muscle; however, a reduction in inward potassium movement is thought to lead to sodium channel inactivation and persistent membrane depolarization.",
"   </p>",
"   <p>",
"    There is little information on the treatment or prognosis of periodic paralysis in this setting. Myopathic weakness is described in some cases of Andersen syndrome, and myopathic changes and tubular aggregates are described on muscle biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Treatment is complicated by the potential to precipitate cardiac arrhythmias; diuretics are contraindicated in patients with the long QT syndrome. Carbonic anhydrase inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    and dichlorphenamide, are reportedly useful in controlling attacks of weakness in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9193/abstract/10,66,68,69\">",
"     10,66,68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/10/33954?source=see_link\">",
"       \"Patient information: Periodic paralysis syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemic PP is a rare inherited neuromuscular disorder, related to a defect in muscle ion channels, and manifest by episodes of painless muscle weakness that may be triggered by rest after vigorous exercise, stress, or a high-carbohydrate meal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The distinguishing clinical features of hypokalemic PP in contrast to other periodic paralysis disorders: thyrotoxic periodic paralysis, hyperkalemic periodic paralysis, and the Andersen syndrome, are summarized in the Table (",
"      <a class=\"graphic graphic_table graphicRef65215 \" href=\"UTD.htm?13/14/13549\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In an acute attack, the diagnosis of familial hypokalemic PP is made by documentation of hypokalemia and excluding thyrotoxicosis and secondary causes of hypokalemia (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      An electrocardiogram (ECG) should also be performed in all patients with periodic paralysis to exclude a long QT or QU interval suggesting Andersen syndrome (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Andersen syndrome'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Genetic testing is available for most, but not all of the mutations underlying hypokalemic PP. Genetic testing may be unnecessary if there is an established family history. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When genetic testing is negative, electromyography (EMG) can be useful in the interictal evaluation of patients with periodic paralysis, distinguishing hypokalemic PP from other periodic paralyses and other causes of intermittent weakness. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Electromyography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend not performing provocative testing with glucose loading or insulin administration as a routine test for hypokalemic PP. Monitoring weakness and potassium levels before and after exercise or ACTH administration is a safer alternative (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Provocative testing'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In an acute disabling attack, we recommend administering oral potassium (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Patients should be on cardiac monitoring, hypokalemia should be verified prior to treatment, and potassium levels should be monitored for potential rebound hyperkalemia for 24 hours. A suggested treatment protocol is potassium 30 meq every 30 minutes until hypokalemia and weakness resolve. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Acute treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonpharmacologic preventive strategies in hypokalemic PP include avoiding strenuous exercise and high-carbohydrate loads. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Preventive treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who continue to have disabling attacks, we recommend prophylactic treatment with a carbonic anhydrase inhibitor, either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      250 mg twice daily or dichlorphenamide 50 mg twice daily (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Because a minority of patients have more attacks with this treatment, close monitoring is recommended during initiation.",
"      <br/>",
"      <br/>",
"      We suggest potassium-sparing diuretics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      100 mg daily) as a supplement to the carbonic anhydrase inhibitor, or as an alternative if a patient worsens on or cannot tolerate the carbonic anhydrase inhibitor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Preventive treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with hypokalemic PP develop a myopathy in later life. The severity is variable. There are no known strategies to prevent or ameliorate the development of weakness. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Andersen syndrome is a rare inherited disorder, manifest by a triad of periodic paralysis (which may be associated with low, normal, or high potassium levels), ventricular arrhythmias, and dysmorphic features. A long QT or long QU interval on ECG suggests this disorder in a patient with periodic paralysis. Carbonic anhydrase inhibitors are reported to limit attacks of weakness in some patients. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Andersen syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link&amp;anchor=H24#H24\">",
"       \"Clinical features of congenital long QT syndrome\", section on 'Andersen syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/1\">",
"      Fontaine B. Periodic paralysis. Adv Genet 2008; 63:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/2\">",
"      Fontaine B, Lapie P, Plassart E, et al. Periodic paralysis and voltage-gated ion channels. Kidney Int 1996; 49:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/3\">",
"      Ober KP. Thyrotoxic periodic paralysis in the United States. Report of 7 cases and review of the literature. Medicine (Baltimore) 1992; 71:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/4\">",
"      Chan A, Shinde R, Chow CC, et al. In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis. BMJ 1991; 303:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/5\">",
"      Ko GT, Chow CC, Yeung VT, et al. Thyrotoxic periodic paralysis in a Chinese population. QJM 1996; 89:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/6\">",
"      Lin SH. Thyrotoxic periodic paralysis. Mayo Clin Proc 2005; 80:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/7\">",
"      Kung AW. Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge. J Clin Endocrinol Metab 2006; 91:2490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/8\">",
"      Elbaz A, Vale-Santos J, Jurkat-Rott K, et al. Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families. Am J Hum Genet 1995; 56:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/9\">",
"      Miller TM, Dias da Silva MR, Miller HA, et al. Correlating phenotype and genotype in the periodic paralyses. Neurology 2004; 63:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/10\">",
"      Venance SL, Cannon SC, Fialho D, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain 2006; 129:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/11\">",
"      Pt&aacute;cek LJ, Tawil R, Griggs RC, et al. Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell 1994; 77:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/12\">",
"      Sill&eacute;n A, S&oslash;rensen T, Kantola I, et al. Identification of mutations in the CACNL1A3 gene in 13 families of Scandinavian origin having hypokalemic periodic paralysis and evidence of a founder effect in Danish families. Am J Med Genet 1997; 69:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/13\">",
"      Wang Q, Liu M, Xu C, et al. Novel CACNA1S mutation causes autosomal dominant hypokalemic periodic paralysis in a Chinese family. J Mol Med (Berl) 2005; 83:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/14\">",
"      Matthews E, Labrum R, Sweeney MG, et al. Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology 2009; 72:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/15\">",
"      Sternberg D, Maisonobe T, Jurkat-Rott K, et al. Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A. Brain 2001; 124:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/16\">",
"      Bulman DE, Scoggan KA, van Oene MD, et al. A novel sodium channel mutation in a family with hypokalemic periodic paralysis. Neurology 1999; 53:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/17\">",
"      Lapie P, Goudet C, Nargeot J, et al. Electrophysiological properties of the hypokalaemic periodic paralysis mutation (R528H) of the skeletal muscle alpha 1s subunit as expressed in mouse L cells. FEBS Lett 1996; 382:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/18\">",
"      Morrill JA, Brown RH Jr, Cannon SC. Gating of the L-type Ca channel in human skeletal myotubes: an activation defect caused by the hypokalemic periodic paralysis mutation R528H. J Neurosci 1998; 18:10320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/19\">",
"      Tanabe T, Beam KG, Powell JA, Numa S. Restoration of excitation-contraction coupling and slow calcium current in dysgenic muscle by dihydropyridine receptor complementary DNA. Nature 1988; 336:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/20\">",
"      Tricarico D, Servidei S, Tonali P, et al. Impairment of skeletal muscle adenosine triphosphate-sensitive K+ channels in patients with hypokalemic periodic paralysis. J Clin Invest 1999; 103:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/21\">",
"      Ruff RL. Insulin acts in hypokalemic periodic paralysis by reducing inward rectifier K+ current. Neurology 1999; 53:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/22\">",
"      Francis DG, Rybalchenko V, Struyk A, Cannon SC. Leaky sodium channels from voltage sensor mutations in periodic paralysis, but not paramyotonia. Neurology 2011; 76:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/23\">",
"      Sokolov S, Scheuer T, Catterall WA. Gating pore current in an inherited ion channelopathy. Nature 2007; 446:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/24\">",
"      Links TP, Zwarts MJ, Wilmink JT, et al. Permanent muscle weakness in familial hypokalaemic periodic paralysis. Clinical, radiological and pathological aspects. Brain 1990; 113 ( Pt 6):1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/25\">",
"      Gold R, Reichmann H. Muscle pathology correlates with permanent weakness in hypokalemic periodic paralysis: a case report. Acta Neuropathol 1992; 84:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/26\">",
"      Griggs RC, Engel WK, Resnick JS. Acetazolamide treatment of hypokalemic periodic paralysis. Prevention of attacks and improvement of persistent weakness. Ann Intern Med 1970; 73:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/27\">",
"      Dalakas MC, Engel WK. Treatment of \"permanent\" muscle weakness in familial Hypokalemic Periodic Paralysis. Muscle Nerve 1983; 6:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/28\">",
"      Links TP, Smit AJ, Molenaar WM, et al. Familial hypokalemic periodic paralysis. Clinical, diagnostic and therapeutic aspects. J Neurol Sci 1994; 122:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/29\">",
"      Cheng CJ, Chen YH, Chau T, Lin SH. A hidden cause of hypokalemic paralysis in a patient with prostate cancer. Support Care Cancer 2004; 12:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/30\">",
"      Fujimoto T, Shiiki H, Takahi Y, Dohi K. Primary Sj&ouml;gren's syndrome presenting as hypokalaemic periodic paralysis and respiratory arrest. Clin Rheumatol 2001; 20:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/31\">",
"      Chang YC, Huang CC, Chiou YY, Yu CY. Renal tubular acidosis complicated with hypokalemic periodic paralysis. Pediatr Neurol 1995; 13:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/32\">",
"      Agarwal AK, Wadhwa S, Wali M. Hypokalaemic periodic paralysis associated with thyrotoxicosis. J Assoc Physicians India 1994; 42:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/33\">",
"      Ahlawat SK, Sachdev A. Hypokalaemic paralysis. Postgrad Med J 1999; 75:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/34\">",
"      Lin SH, Lin YF, Chen DT, et al. Laboratory tests to determine the cause of hypokalemia and paralysis. Arch Intern Med 2004; 164:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/35\">",
"      Lin SH, Lin YF, Halperin ML. Hypokalaemia and paralysis. QJM 2001; 94:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/36\">",
"      Liu PY, Jeng CY. Severe hypophosphatemia in a patient with diabetic ketoacidosis and acute respiratory failure. J Chin Med Assoc 2004; 67:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/37\">",
"      Ng HY, Lin SH, Hsu CY, et al. Hypokalemic paralysis due to Gitelman syndrome: a family study. Neurology 2006; 67:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/38\">",
"      Phakdeekitcharoen B, Ruangraksa C, Radinahamed P. Hypokalaemia and paralysis in the Thai population. Nephrol Dial Transplant 2004; 19:2013.",
"     </a>",
"    </li>",
"    <li>",
"     Cannon SC, George AL. Pathophysiology of myotonia and periodic paralysis. In: Diseases of the Nervous System, 3rd, Asbury AK, McKhann GM, McDonald WI, et al (Eds), Cambridge University Press, Cambridge 2002. p.1183.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/40\">",
"      Streeten DH, Speller PJ, Fellerman H. Use of corticotropin-induced potassium changes in the diagnosis of both hypo- and hyperkalemic periodic paralysis. Eur Neurol 1993; 33:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/41\">",
"      McManis PG, Lambert EH, Daube JR. The exercise test in periodic paralysis. Muscle Nerve 1986; 9:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/42\">",
"      Tengan CH, Antunes AC, Gabbai AA, Manzano GM. The exercise test as a monitor of disease status in hypokalaemic periodic paralysis. J Neurol Neurosurg Psychiatry 2004; 75:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/43\">",
"      Kuntzer T, Flocard F, Vial C, et al. Exercise test in muscle channelopathies and other muscle disorders. Muscle Nerve 2000; 23:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/44\">",
"      Fournier E, Arzel M, Sternberg D, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol 2004; 56:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/45\">",
"      Sugiura Y, Makita N, Li L, et al. Cold induces shifts of voltage dependence in mutant SCN4A, causing hypokalemic periodic paralysis. Neurology 2003; 61:914.",
"     </a>",
"    </li>",
"    <li>",
"     Rose BD, Post TW. linical Physiology of Acid-Base and Electrolyte Disorders, 5th, McGraw-Hill, New York 2001. p.836.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/47\">",
"      Manoukian MA, Foote JA, Crapo LM. Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes. Arch Intern Med 1999; 159:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/48\">",
"      Tassone H, Moulin A, Henderson SO. The pitfalls of potassium replacement in thyrotoxic periodic paralysis: a case report and review of the literature. J Emerg Med 2004; 26:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/49\">",
"      Lu KC, Hsu YJ, Chiu JS, et al. Effects of potassium supplementation on the recovery of thyrotoxic periodic paralysis. Am J Emerg Med 2004; 22:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/50\">",
"      Loh KC, Pinheiro L, Ng KS. Thyrotoxic periodic paralysis complicated by near-fatal ventricular arrhythmias. Singapore Med J 2005; 46:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/51\">",
"      Griggs RC, Resnick J, Engel WK. Intravenous treatment of hypokalemic periodic paralysis. Arch Neurol 1983; 40:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/52\">",
"      Caciotti A, Morrone A, Domenici R, et al. Severe prognosis in a large family with hypokalemic periodic paralysis. Muscle Nerve 2003; 27:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/53\">",
"      Layzer RB. Periodic paralysis and the sodium-potassium pump. Ann Neurol 1982; 11:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/54\">",
"      Resnick JS, Engel WK, Griggs RC, Stam AC. Acetazolamide prophylaxis in hypokalemic periodic paralysis. N Engl J Med 1968; 278:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/55\">",
"      Tawil R, McDermott MP, Brown R Jr, et al. Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann Neurol 2000; 47:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/56\">",
"      Sansone V, Meola G, Links TP, et al. Treatment for periodic paralysis. Cochrane Database Syst Rev 2008; :CD005045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/57\">",
"      Links TP, Arnoldus EP, Wintzen AR, et al. The calcium channel blocker verapamil in hypokalemic periodic paralysis. Muscle Nerve 1998; 21:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/58\">",
"      Matthews E, Portaro S, Ke Q, et al. Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype. Neurology 2011; 77:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/59\">",
"      Fiore DM, Strober JB. Treatment of hypokalemic periodic paralysis with topiramate. Muscle Nerve 2011; 43:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/60\">",
"      Tricarico D, Barbieri M, Camerino DC. Acetazolamide opens the muscular KCa2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis. Ann Neurol 2000; 48:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/61\">",
"      Tricarico D, Barbieri M, Mele A, et al. Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats. FASEB J 2004; 18:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/62\">",
"      Ligtenberg JJ, Van Haeften TW, Van Der Kolk LE, et al. Normal insulin release during sustained hyperglycaemia in hypokalaemic periodic paralysis: role of the potassium channel opener pinacidil in impaired muscle strength. Clin Sci (Lond) 1996; 91:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/63\">",
"      Kim JB, Lee KY, Hur JK. A Korean family of hypokalemic periodic paralysis with mutation in a voltage-gated calcium channel (R1239G). J Korean Med Sci 2005; 20:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/64\">",
"      Torres CF, Griggs RC, Moxley RT, Bender AN. Hypokalemic periodic paralysis exacerbated by acetazolamide. Neurology 1981; 31:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/65\">",
"      Bendahhou S, Cummins TR, Griggs RC, et al. Sodium channel inactivation defects are associated with acetazolamide-exacerbated hypokalemic periodic paralysis. Ann Neurol 2001; 50:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/66\">",
"      Tristani-Firouzi M, Jensen JL, Donaldson MR, et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest 2002; 110:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/67\">",
"      Sansone V, Griggs RC, Meola G, et al. Andersen's syndrome: a distinct periodic paralysis. Ann Neurol 1997; 42:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/68\">",
"      Tawil R, Ptacek LJ, Pavlakis SG, et al. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol 1994; 35:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9193/abstract/69\">",
"      Davies NP, Imbrici P, Fialho D, et al. Andersen-Tawil syndrome: new potassium channel mutations and possible phenotypic variation. Neurology 2005; 65:1083.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5150 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_62_9193=[""].join("\n");
var outline_f8_62_9193=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Initial laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Provocative testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Electromyography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ACUTE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PREVENTIVE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ANDERSEN SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5150\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5150|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/14/13549\" title=\"table 1\">",
"      Periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5150|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?18/38/19043\" title=\"waveform 1\">",
"      Hypokalemia tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?26/24/27008\" title=\"waveform 2\">",
"      Prolonged QT interval tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=related_link\">",
"      Approach to the metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=related_link\">",
"      Diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=related_link\">",
"      ECG tutorial: Miscellaneous diagnoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/9/9366?source=related_link\">",
"      Evaluation of the patient with hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/54/871?source=related_link\">",
"      Hyperkalemic periodic paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=related_link\">",
"      Neurologic manifestations of hyperthyroidism and Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/10/33954?source=related_link\">",
"      Patient information: Periodic paralysis syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=related_link\">",
"      Susceptibility to malignant hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22119?source=related_link\">",
"      Thyrotoxic periodic paralysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_62_9194="Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism";
var content_f8_62_9194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/62/9194/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/62/9194/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/62/9194/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/62/9194/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/62/9194/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/62/9194/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/62/9194/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolytic anemia is defined as a shortening of red blood cell (RBC) survival to less than 100 days (normal: approximately 120 days) due to an increased rate of destruction of RBCs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemolytic anemia is caused by one of two mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormalities arising from within the RBC",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      its membrane (intracorpuscular defects). These are usually congenital (eg, sickle cell anemia, thalassemia, glucose-6-phosphate dehydrogenase (G6PD) deficiency, hereditary spherocytosis), but may rarely be acquired, as in paroxysmal nocturnal hemoglobinuria.",
"     </li>",
"     <li>",
"      Abnormalities in the environment of the RBC. These processes are, by definition, extracorpuscular, and the ensuing hemolysis is called extrinsic hemolytic anemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Extrinsic hemolytic anemia is often due to immune mechanisms, as in warm and cold agglutinin hemolytic anemia. However, there are many nonimmune causes, including systemic diseases, mechanical destruction (ie, fragmentation hemolysis), increased destruction within an enlarged spleen (hypersplenism), and the action of toxins and drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link&amp;anchor=H10#H10\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Causes of hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extrinsic hemolytic anemia due to fragmentation hemolysis and hypersplenism will be reviewed here. Extrinsic hemolysis due to systemic disease and oxidative hemolysis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=see_link\">",
"     \"Extrinsic nonimmune hemolytic anemia due to systemic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=see_link\">",
"     \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irrespective of the site of the increased RBC destruction, whether extravascular (eg, within the liver or spleen), or within the circulation (ie, intravascular), the laboratory signs of active hemolysis usually include the following. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased concentration of serum indirect bilirubin",
"     </li>",
"     <li>",
"      Increased concentration of serum lactate dehydrogenase",
"     </li>",
"     <li>",
"      Decreased concentration of serum haptoglobin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A major distinction between intravascular and extravascular hemolysis is the liberation of free hemoglobin into the circulation in the former situation. Thus, the signs of",
"    <strong>",
"     intravascular hemolysis",
"    </strong>",
"    include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased concentrations of free hemoglobin in the plasma",
"     </li>",
"     <li>",
"      The presence of free hemoglobin in the urine (hemoglobinuria), which produces a red, heme-positive urine supernatant in association with red plasma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H4#H4\">",
"       \"Urinalysis in the diagnosis of kidney disease\", section on 'Red to brown urine'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The presence of hemosiderin in the urine (hemosiderinuria), which is a more chronic event.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intravascular hemolysis is associated with a rapid reduction in serum haptoglobin concentrations, occasionally to undetectable levels. However, serum haptoglobin is not a specific indicator of intravascular hemolysis since it can be low or absent with brisk extravascular hemolysis. Another problem is that haptoglobin is an acute phase reactant; accordingly, serum concentrations in patients with concomitant infection or inflammation may be normal in the presence of hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FRAGMENTATION HEMOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with one of the forms of fragmentation hemolysis present with varying degrees of anemia, with evidence of red cell fragmentation, called schistocytes or helmet cells on peripheral blood smear (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"     picture 1",
"    </a>",
"    ). Since microvascular abnormalities are frequently involved, the condition is often called a microangiopathic hemolytic anemia, or thrombotic microangiopathy (TMA) when associated with thrombotic changes and frequently with thrombocytopenia.",
"   </p>",
"   <p>",
"    As will be described below, fragmentation hemolysis may be associated with activation of the coagulation system in disseminated intravascular coagulation (DIC) or with primary platelet activation in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS). In these settings, thrombocytopenia typically occurs and affected patients can develop symptoms from either thrombosis or bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A frequently asked question has been how many schistocytes need to be present on a peripheral blood smear to suggest fragmentation hemolysis. The answer requires some estimate of the prevalence of schistocytes in normal subjects.",
"   </p>",
"   <p>",
"    This issue was addressed in a study of 40 normal individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/2\">",
"     2",
"    </a>",
"    ]. Schistocytes were found on the peripheral blood smear in 23 (58 percent). However, they always comprised less than 0.5 percent of the red cell population, with a mean of 0.05 percent. Schistocytes were seen in 80 to 100 percent of patients with renal disease (mean 0.2 percent), preeclampsia (mean 0.25 percent), and in patients with normally functioning mechanical heart valves (mean 0.18 percent).",
"   </p>",
"   <p>",
"    In contrast, the mean schistocyte count in six patients with TTP-HUS was 8.4 percent (range 1 to 18 percent), and ranged from 0.5 to 9 percent in a second study [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/3\">",
"     3",
"    </a>",
"    ]. In the appropriate clinical setting, and in absence of other known causes of thrombotic microangiopathy, it has been concluded that a schistocyte count &gt;1.0 percent, or observing &ge;2 schistocytes in a microscopic field with an overall magnification of 1000, is strongly suggestive of a diagnosis of TTP-HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/2\">",
"     2",
"    </a>",
"    ], while a schistocyte count &lt;1.0 percent is useful for ruling out thrombotic microangiopathy, with a negative predictive value of 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a number of studies, schistocyte counting by automated cell counters correlated highly with counts obtained by microscopic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. This was especially true at levels above 1 percent. The Advia 120 automated cell counter had a tendency to overestimate the schistocyte count by approximately 0.4 percent, with a problem setting threshold levels for distinguishing between the presence or absence of schistocytes with sufficient sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=see_link&amp;anchor=H28#H28\">",
"     \"Automated hematology instrumentation\", section on 'Siemens Advia (and H series)'",
"    </a>",
"    .) Accordingly, the \"gold standard\" for schistocyte determination remains examination of a suitably prepared peripheral blood smear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1962, Brain and others identified a possible relationship between vascular lesions and RBC fragmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/7\">",
"     7",
"    </a>",
"    ]. They postulated that the lesions either produced shearing forces sufficiently strong to fragment the red cells or led to inflammation of small vessel walls, which in turn generated fibrin strands that literally cut the passing red cell into irregular pieces (",
"    <a class=\"graphic graphic_picture graphicRef81610 \" href=\"UTD.htm?4/52/4932\">",
"     picture 2",
"    </a>",
"    ). In vitro studies have shown that shear stresses of &gt;3000",
"    <span class=\"nowrap\">",
"     dynes/cm(2)",
"    </span>",
"    cause RBC fragmentation; in vivo, peak shear stresses of up to 6000",
"    <span class=\"nowrap\">",
"     dynes/cm(2)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    very rapid acceleration or deceleration have been seen in patients with fragmentation hemolysis due to mitral prosthetic valve regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a baboon model in which injection of C4b-binding proteins and Escherichia coli produced a picture of DIC with microangiopathic hemolysis and thrombocytopenia, treatment with a monoclonal antibody directed against the platelet glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptor reduced microangiopathic hemolysis and renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/9\">",
"     9",
"    </a>",
"    ]. This observation indicates a role for platelets in the microangiopathic process.",
"   </p>",
"   <p>",
"    The red cell membrane is viscoelastic and has self-sealing properties; as a result, little hemoglobin leaks out when the cell is cut. The smaller red cell fragments continue to display evidence of the shearing event or distortion in the form of the typical irregular shapes (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"     picture 1",
"    </a>",
"    ), most typically in the form of helmet-shaped red cells (",
"    <a class=\"graphic graphic_picture graphicRef50715 \" href=\"UTD.htm?22/13/22739\">",
"     picture 3",
"    </a>",
"    ). In addition, prolonged distortion of the membrane produces an increase in rigidity. The irregular shapes and rigidity interfere with the ability of the red cells to fold, elongate, and deform sufficiently to pass through 3 micron capillaries and even smaller slits in the walls of the sinusoids of the reticuloendothelial system. This abnormality leads to their destruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fragmentation hemolysis is seen in a number of disorders, and the underlying cause is often apparent from the clinical setting, eg, a prosthetic heart valve leading to Waring blender syndrome (",
"    <a class=\"graphic graphic_picture graphicRef74544 \" href=\"UTD.htm?23/11/23734\">",
"     picture 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/10\">",
"     10",
"    </a>",
"    ]. Some of the causes are reviewed in detail elsewhere and will be briefly mentioned here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Disseminated intravascular coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated intravascular coagulation (DIC) is characterized by activation of the coagulation cascade, usually due to the release or increased expression of tissue factor. This is followed by the deposition of fibrin and platelet thrombi within small vessels, and mechanical shearing of red cells on the fibrin strands (",
"    <a class=\"graphic graphic_picture graphicRef81610 \" href=\"UTD.htm?4/52/4932\">",
"     picture 2",
"    </a>",
"    ). DIC has a variety of causes, the most common of which are sepsis, trauma, malignancy, and obstetrical complications; less common causes include large hemangiomas (Kasabach-Merritt syndrome) and large abdominal aortic aneurysms (",
"    <a class=\"graphic graphic_table graphicRef58104 \" href=\"UTD.htm?8/28/8652\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=see_link\">",
"     \"Pathogenesis and etiology of disseminated intravascular coagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     HELLP syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HELLP syndrome (",
"    <strong>",
"     h",
"    </strong>",
"    emolysis with a microangiopathic blood smear,",
"    <strong>",
"     e",
"    </strong>",
"    levated",
"    <strong>",
"     l",
"    </strong>",
"    iver enzymes, and a",
"    <strong>",
"     l",
"    </strong>",
"    ow",
"    <strong>",
"     p",
"    </strong>",
"    latelet count) is a serious complication of pregnancy, which can occur without other signs of preeclampsia or hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. It is often associated with DIC and can produce hepatic rupture, visual failure, seizures, and heart failure. Treatment consists of prompt delivery of the fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"     \"HELLP syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical picture of TTP-HUS is generally dramatic and acute and, as mentioned above, results from primary platelet activation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/13\">",
"     13",
"    </a>",
"    ]. The triad of microangiopathic hemolytic anemia, thrombocytopenia, and a varying degree of renal failure has been called HUS, while the addition of fever and neurologic abnormalities has been called TTP. However, the distinction between TTP and HUS is supported by the very low levels of ADAMTS 13 seen in TTP and not in HUS. However, both disorders may share a similar pathogenetic mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link&amp;anchor=H1#H1\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Introduction and disease definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of disorders have been associated with TTP and HUS, which are generally different from those that cause DIC (",
"    <a class=\"graphic graphic_table graphicRef69868 \" href=\"UTD.htm?4/25/4508\">",
"     table 2",
"    </a>",
"    ). A frequent feature in TTP is increased amounts of unusually large multimers of von Willebrand factor, which may attach to activated platelets and promote platelet aggregation. Acquired disease is frequently associated with antibodies to von Willebrand factor-cleaving protease or endothelial injury, while familial disease is associated with a constitutional deficiency of the protease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vessels supplying malignant tumors are thought to be structurally abnormal. They exhibit the same sort of fibrin stranding that is seen in DIC and TTP-HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, there may be a hypercoagulable state associated with cancer (ie, migratory superficial thrombophlebitis or Trousseau's Syndrome) which causes DIC. The hypercoagulable state is primarily due to two factors expressed by circulating tumor cells: tissue factor and cancer procoagulant, a calcium-dependent cysteine protease that is not seen in normally differentiated tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1224?source=see_link\">",
"     \"Pathogenesis of the hypercoagulable state associated with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=see_link\">",
"     \"Hematologic consequences of malignancy: Anemia and bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Malignant hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reversible microangiopathic hemolytic anemia and thrombocytopenia have been seen in patients with malignant hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/17\">",
"     17",
"    </a>",
"    ]. On occasion, the patient with malignant hypertension may present with microangiopathic hemolysis, renal insufficiency, and thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/18\">",
"     18",
"    </a>",
"    ]. The presumed mechanism is the associated",
"    <span class=\"nowrap\">",
"     endothelial/vascular",
"    </span>",
"    injury, which, in turn, leads to fibrin strand formation, shearing of RBCs, and the trapping and removal of platelets. Very rapid control of the hypertension is critical; with good control the survival rate at 5 years is 75 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link&amp;anchor=H2#H2\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\", section on 'Mechanisms of vascular injury'",
"    </a>",
"    .) There appears to be a correlation between plasma renin levels, renal dysfunction, and microangiopathic findings, thereby pointing to the possible role of renin accelerated vascular damage in the pathophysiology of this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study of 97 patients with malignant hypertension, 27 percent had microangiopathic hemolytic anemia. The group with MAHA was clinically more severe, with higher creatinine levels, higher systolic BP, and a greater need for dialysis (58 versus 3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Scleroderma renal crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with scleroderma renal crisis present with acute onset of renal failure, moderate to marked hypertension, and may have a microangiopathic blood picture. Rapid control of the hypertension is required for reversal of this potentially fatal presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=see_link\">",
"     \"Scleroderma renal crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Malfunctioning cardiac valves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamic turbulence can lead to microangiopathic hemolytic anemia and thrombocytopenia. This is most often seen in patients with leaky prosthetic valves or other foreign materials, such as a patched atrioventricular shunt (",
"    <a class=\"graphic graphic_picture graphicRef74544 \" href=\"UTD.htm?23/11/23734\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/8,21\">",
"     8,21",
"    </a>",
"    ]. Because of the high pressure gradient, it is usually assumed that aortic valve prostheses cause more hemolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H18#H18\">",
"     \"Complications of prosthetic heart valves\", section on 'Hemolytic anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, poorly functioning mitral valve prostheses can also cause microangiopathic hemolysis. As an example, in one study of 32 patients with hemolytic anemia following mitral valve repair, hemolysis became apparent at a median interval of 3 months (range: 1 month to 3 years) following initial mitral valve surgery, with hematocrit levels averaging 27 percent; 22 patients required RBC transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/22\">",
"     22",
"    </a>",
"    ]. Mitral valve replacement or re-repair was performed in 31 patients with resolution of the hemolytic anemia. In one patient recurrent mechanical hemolysis developed caused by a perivalvular leak after mitral valve replacement.",
"   </p>",
"   <p>",
"    Less common causes include atrioventricular malformations, calcific aortic stenosis, left atria myxoma, and cardiac metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/23\">",
"     23",
"    </a>",
"    ]. The combination of blood flow across a pressure gradient, disruption by shear stress, and, in particular, impact on a foreign nonendothelialized surface, leads to traumatic disruption of red cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Kasabach Merritt syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Kasabach Merritt phenomenon was first described in 1940 as a syndrome of consumptive coagulopathy with capillary hemangiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/24\">",
"     24",
"    </a>",
"    ]. However, more modern investigations have shown that this phenomenon is associated with kaposiform hemangioendotheliomas, an aggressive form of giant hemangioma, and not true common hemangiomas of infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Lesions are noted at birth in approximately 50 percent of patients and the male to female ratio approaches 1:1. Common locations, in order of frequency, include: trunk (including retroperitoneum), arms and shoulder, lower extremity, and cervicofacial. All patients have severe thrombocytopenia, hypofibrinogenemia, elevated fibrin degradation products, and fragmentation of red blood cells. Treatments have included corticosteroids, interferon alfa, surgery, embolization, and chemotherapeutic agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and actinomycin D [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Insertion of foreign bodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The insertion of certain foreign bodies into the circulation, such as transjugular intrahepatic portosystemic shunts (TIPS) and coil embolization, can lead to microangiopathic hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In one series, transjugular intrahepatic portosystemic shunts (TIPS) caused the syndrome in approximately 10 percent of patients. The hemolysis, which was thought to be due to shear stress or direct mechanical trauma in the shunt, disappeared after 12 to 15 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15448?source=see_link&amp;anchor=H8#H8\">",
"     \"Complications of transjugular intrahepatic portosystemic shunts\", section on 'Hemolytic anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer chemotherapy and other drugs may play a role in the occurrence of fragmentation hemolysis, producing a picture similar to TTP-HUS. In one series of 581 patients treated for breast cancer with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    , for example, 2.6 percent developed hemolytic anemia and thrombocytopenia with thrombotic microangiopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/32\">",
"     32",
"    </a>",
"    ]. A similar picture has been described",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C and the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    and cisplatin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. A variety of other drugs has also been associated with this syndrome including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef69868 \" href=\"UTD.htm?4/25/4508\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H19#H19\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, a case report indicated that cocaine abuse can cause the syndrome of thrombotic microangiopathy, thrombocytopenia, and acute renal failure. The patient survived after transfusion with fresh frozen plasma and hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/35\">",
"     35",
"    </a>",
"    ]. One month later, the patient again used cocaine, with worsening of renal failure, anemia, and thrombocytopenia.",
"   </p>",
"   <p>",
"    Thrombotic microangiopathy involving the kidney has also been described in association with the use of anti-vascular endothelial growth factor (VEGF) antibodies (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/36-38\">",
"     36-38",
"    </a>",
"    ], and microangiopathic hemolytic anemia has been described in patients with solid tumors being treated in a phase I study with a combination of bevacizumab and the tyrosine kinase",
"    <span class=\"nowrap\">",
"     inhibitor/VEGF",
"    </span>",
"    receptor inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link&amp;anchor=H34#H34\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'VEGF pathway inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Other diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other hemolytic disorders involving small vessels are related to fibrin deposition, with red cell entrapment and fragmentation because of the force of blood flow. These include eclampsia, renal allograft rejection, paroxysmal nocturnal hemoglobinuria, scleroderma, and vasculitides such as polyarteritis nodosa and granulomatosis with polyangiitis (Wegener's granulomatosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The \"catastrophic\" antiphospholipid syndrome can also produce this syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Hematologic manifestations'",
"    </a>",
"    .) Diagnosis requires suspicion followed by measurement of anticardiolipin antibodies or the lupus anticoagulant. Treatment includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    anticoagulation, intravenous corticosteroids, as well as plasmapheresis and replacement with fresh frozen plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of the antiphospholipid syndrome\", section on 'Hematologic manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathognomonic finding in fragmentation hemolysis is the presence of fragmented RBCs on the peripheral smear (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"     picture 1",
"    </a>",
"    ), usually in conjunction with anemia and perhaps thrombocytopenia. The history often provides clues to the underlying disease process.",
"   </p>",
"   <p>",
"    An important distinction is between TTP-HUS and DIC which can produce similar clinical changes but are treated differently. The pathogenetic distinction between TTP-HUS (primary platelet activation) and DIC (activation of the coagulation pathway) results in different coagulation abnormalities that usually permit these disorders to be distinguished. Patients with TTP-HUS present with thrombocytopenia and a microangiopathic blood smear but, since there is primary platelet consumption, usually normal levels of the coagulation components and little or no prolongation of the prothrombin time (PT) or activated partial thromboplastin time (aPTT) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/43\">",
"     43",
"    </a>",
"    ]; these changes, including low concentrations of fibrinogen and increased concentrations of D-dimer, are characteristic findings in DIC.",
"   </p>",
"   <p>",
"    The one exception to this general rule occurs in patients with a TTP-HUS-like picture due to the lupus anticoagulant, which can prolong the PTT and less often the PT by interfering with the in vitro assembly of the prothrombinase complex during the laboratory measurement of these parameters. However, the fibrinogen and D-dimer values will not be those of DIC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of any of the above causes of fragmentation hemolysis is primarily directed at the underlying disease or event. Examples include antibiotics for sepsis in DIC, plasma exchange in TTP, antihypertensive therapy in malignant hypertension and scleroderma renal crisis, and replacement of a prosthetic heart valve or other foreign material if the hemolysis produces a disabling transfusion requirement. In addition, iron or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    should be provided to optimize red cell production if the patient is deficient in these nutrients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     INTRAVASCULAR HEMOLYSIS FROM OTHER FORMS OF MECHANICAL DAMAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;RBCs can be physically damaged by heat, mechanical trauma, or osmotic attack. These situations do not affect the platelet count.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Heat denaturation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal RBCs will undergo budding and fragmentation when exposed to a temperature of 49&ordm;C in vitro. In some of the hereditary hemolytic anemias, this occurs at temperatures as low as 46&ordm;C. There are isolated circumstances in which temperatures have been generated that are sufficient to cause heat denaturation of RBCs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occasionally, blood warming devices, used to bring transfused blood products to body temperature before infusion, as in patients with cold agglutinin disease, have malfunctioned and excessively warmed the red cells about to be transfused. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=see_link&amp;anchor=H5#H5\">",
"       \"Transfusion reactions caused by chemical and physical agents\", section on 'Blood warmers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In one case, a patient's mother decided to warm red cells with a hot water bottle, reasoning that such cells would cause less vein irritation to her child. The transfusion was followed by evidence of both intravascular and extravascular hemolysis, and the peripheral smear showed red cell budding and fragmentation.",
"     </li>",
"     <li>",
"      Hemolysis can occur in patients who have sustained very extensive thermal burns [",
"      <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/44\">",
"       44",
"      </a>",
"      ]. In comparison, body temperature is usually below 42&ordm;C in patients with heatstroke, a temperature at which little RBC denaturation occurs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Mechanical trauma",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     March hemoglobinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic example of red cell damage due to mechanical trauma is march hemoglobinuria (also called foot-strike hemolysis, runners hemoglobinuria), which occurs in a number of settings such as [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Soldiers after a long march",
"     </li>",
"     <li>",
"      Karate or bongo drumming enthusiasts following practice",
"     </li>",
"     <li>",
"      Marathon runners or joggers, especially after running on hard surfaces, when using poorly cushioned running shoes, or when typical training distance is increased",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although microangiopathic changes in red cells can be seen, anemia is rare, and reticulocytosis is uncommon. Intravascular red cell destruction is thought to be caused by direct trauma to the red cells in vessels of the extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Consistent with this hypothesis is the observation that switching the jogging path or using better footwear relieves the problem [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/51\">",
"     51",
"    </a>",
"    ]. Some patients may be predisposed to develop this complication due to an underlying red cell abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/46,52-56\">",
"     46,52-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In occasional cases, red cells can be mechanically injured by malfunction of cell savers used during abdominal or thoracic surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Thrombectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical trauma to red cells may also occur during the process of thrombectomy, when certain percutaneous mechanical thrombectomy devices are used to disrupt a clot via the process of clot fragmentation and maceration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=see_link&amp;anchor=H23#H23\">",
"     \"Prevention, presentation, and management of saphenous vein graft stenosis\", section on 'Thrombolysis and thrombectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Cardiopulmonary bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;The postperfusion syndrome occurs in some patients following cardiopulmonary bypass; it is characterized by acute intravascular hemolysis and leukopenia as part of a febrile inflammatory clinical picture. Some of these patients go on to develop pulmonary dysfunction and even adult respiratory distress syndrome. Visible hemoglobinemia occurs, with rising plasma hemoglobin levels, and lysed red cell ghosts can be seen in the whole blood and plasma. These ghosts are coated with the complement complex C5b-9 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/59\">",
"     59",
"    </a>",
"    ]. The complement pathway is presumably activated as the blood is passed through the oxygenator.",
"   </p>",
"   <p>",
"    Why complement activation results in a lytic attack on red cells (and also granulocytes) is not known. Treatment involves knowledge of the process and requisite support until spontaneous recovery occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Extracorporeal hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Damage to red cells is an unavoidable side effect of extracorporeal hemodialysis. Acute hemolysis can also occur, mostly due to mechanical issues (eg, obstructions within the extracorporeal circuit, kinking of blood tubing, excessive flow, improper cannula or catheter dimensions) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=see_link&amp;anchor=H5#H5\">",
"     \"Acute complications during hemodialysis\", section on 'Hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Osmotic attack",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abrupt changes in osmolality can cause hemolysis. Freshwater drowning may be associated with sufficient water in the lungs that the red cells swell, as they undergo an in vivo osmotic fragility test in the lung vessels (",
"    <a class=\"graphic graphic_figure graphicRef69042 \" href=\"UTD.htm?11/48/12047\">",
"     figure 1",
"    </a>",
"    ). A similar effect can be induced by the inadvertent use of a very dilute dialysate in patients treated with hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=see_link&amp;anchor=H5#H5\">",
"     \"Acute complications during hemodialysis\", section on 'Hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, saltwater drowning or mistaken infusion or exposure to concentrated hypertonic solutions such as those used in hemodialysis can cause profound dehydration of red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/61,62\">",
"     61,62",
"    </a>",
"    ], producing a situation analogous to xerocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14583?source=see_link\">",
"     \"Xerocytosis\"",
"    </a>",
"    .) To manage such an event, one must recognize its cause, appreciate the shrunken RBCs on peripheral smear, and restore isotonicity as quickly as possible. The use of a hemodialysis device, if available, may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     EXTRAVASCULAR NONIMMUNE HEMOLYSIS DUE TO HYPERSPLENISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spleen is the major organ of the",
"    <span class=\"nowrap\">",
"     monocyte/macrophage",
"    </span>",
"    system. Blood cells leave the splenic arterial bed through afferent arterioles, which pass through lymphoid nodules (the white pulp), and then terminate in the cords of Billroth (the red pulp), into which the blood cells are discharged. The normal slow flow through the cords permits highly selective action on the blood cells by macrophages, which have receptors that can detect alterations in the blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/63\">",
"     63",
"    </a>",
"    ]. These receptors include the Fc receptor for the appropriate portion of the immunoglobulin molecule, receptors for complement components such as C3b, and perhaps receptors that detect alterations in the outer portion of the RBC phospholipid bilayer or in the externally oriented glycopeptides.",
"   </p>",
"   <p>",
"    The macrophage then holds, retards, modifies (&ldquo;pits&rdquo;), or removes (&ldquo;culls&rdquo;) such RBCs. The normal pitting function of the spleen allows it to remove nuclear residua (Howell-Jolly bodies) (",
"    <a class=\"graphic graphic_picture graphicRef60588 \" href=\"UTD.htm?38/45/39638\">",
"     picture 5",
"    </a>",
"    ) and normally occurring endocytic vacuoles (called \"pits\" or \"pocks\" because of their appearance on interference-phase or Nomarski microscopy). The normal culling function of the spleen is exemplified by its removal of senescent RBCs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The blood cells must then traverse the cords in order to approach and pass though slits in the sinus wall to reenter the circulation. These slits are 2 to 3 microns in size and are usually endothelialized on one side, with a macrophage lining on the other side. The normal human adult RBC is a discocyte, with a surface area 40 percent larger than a sphere of that volume. It is this excess surface area that allows RBCs of 8 micron diameter to twist, elongate, and deform sufficiently to squeeze through the 2 to 3 micron slits. This excess of surface area is critical, and the normal RBC has a surface area-to-volume",
"    <span class=\"nowrap\">",
"     (SA/V)",
"    </span>",
"    ratio of about 1.4. Any condition that reduces the",
"    <span class=\"nowrap\">",
"     SA/V",
"    </span>",
"    ratio reduces the ability of RBCs to traverse these sinusoidal slits, because a plump, surface area-depleted sphere cannot undergo the requisite elliptical deformation sufficiently. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factors that interfere with the interaction of the red cell cytosol and membrane will also impair deformability and passage through the slits. As an example, oxidant attack may produce Heinz bodies that come to be adjacent to the membrane. The Heinz bodies interfere with the smooth movement of the membrane over the cytosol, called \"tank treading.\" Such cells are selectively blocked from leaving the splenic cords and entering the sinuses [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=see_link\">",
"     \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\"",
"    </a>",
"    .) In addition, inflammation or infection may enhance the ability of splenic macrophages to attack and ingest RBC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Splenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;All the activities of the spleen are thought to be markedly accentuated in a large spleen. The clinical picture of hypersplenism, which can cause anemia as well as a variable degree of neutropenia and thrombocytopenia due to trapping of neutrophils and platelets, will ensue if the increase in phagocytic activity is sufficiently extensive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H11#H11\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Distributional thrombocytopenia caused by splenomegaly'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is the size of the spleen, not the portal pressure, that primarily determines the degree of RBC sequestration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/65\">",
"     65",
"    </a>",
"    ]. Other factors that may play a role are the state of activation of the splenic macrophages and the size of the small slits between the splenic cords and sinuses. Both macrophages and slits seem to be under a degree of control, as evidenced by variations in splenic removal of RBCs in patients infected with malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical picture of hypersplenic extravascular hemolysis is dominated by the specific cause of the splenomegaly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\"",
"    </a>",
"    .) The hemolysis is associated with a variable degree of anemia, which depends in part upon the magnitude of compensatory increase in RBC production. Although the causes of splenomegaly are legion, there are several general mechanisms of hemolysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stasis and trapping in the spleen are associated with macrophagic attack and remodeling of the red cell surface; the ensuing reduction in the",
"      <span class=\"nowrap\">",
"       SA/V",
"      </span>",
"      ratio leads to spherocytosis.",
"     </li>",
"     <li>",
"      If the red cells undergo a prolonged period of distortion in traversing the cordal-sinus barrier, tailed red cells (eg, teardrop- shaped red cells) will be present as the red cell membranes undergo a plastic change.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In adults, many conditions cause splenomegaly via a number of mechanisms (",
"    <a class=\"graphic graphic_table graphicRef69397 \" href=\"UTD.htm?26/43/27324\">",
"     table 3",
"    </a>",
"    ), but only a few cause massive splenomegaly (eg, below the left and occasionally the right iliac crest). These include chronic myeloid leukemia, agnogenic myeloid metaplasia, lymphoma (usually the less aggressive histologies), hairy cell leukemia, Gaucher disease, kala-azar, and hyperreactive malarial splenomegaly (also called the tropical splenomegaly syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/68\">",
"     68",
"    </a>",
"    ]). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link&amp;anchor=H22#H22\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Causes of splenomegaly'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Treatment of hypersplenism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of hypersplenism depends upon both the etiology of the splenic enlargement and the severity of the hematologic changes. The anemia or pancytopenia is usually not very profound. However, splenectomy may be considered if the anemia or other cytopenia is very severe. It is important to appreciate that massive splenomegaly is frequently associated with expansion of the plasma volume; as a result, the hemoglobin concentration, hematocrit, or red cell count may give a falsely low estimate of the actual red cell mass. If this is suspected, the true RBC mass can be determined by a Cr-51 red cell mass determination, which can also be used to estimate RBC survival.",
"   </p>",
"   <p>",
"    In one study of 19 patients with severe liver disease, hypersplenism, and a mean platelet count of",
"    <span class=\"nowrap\">",
"     15,400/microL,",
"    </span>",
"    successful live donor liver transplantation resulted in a gradual decrease in splenic volume with no significant change in the platelet count [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Kupffer cells and hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;While not strictly a mechanism of hypersplenism, erythrophagocytosis by hepatic Kupffer cells is a prominent finding in patients undergoing graft-versus-host hemolysis after ABO-mismatched liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/62/9194/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88701453\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;This review discusses increased red blood cell destruction (hemolysis) associated with red blood cell fragmentation, intravascular hemolysis, and hypersplenism. In all of these settings, hemolysis is accompanied by varying degrees of anemia, along with increases in serum levels of lactate dehydrogenase (LDH) and indirect bilirubin, and decreases in haptoglobin. An increased number of circulating reticulocytes will be seen",
"    <strong>",
"     only",
"    </strong>",
"    if the bone marrow is able to respond to the induced anemia. Other abnormalities depend upon the clinical setting, and are described below. In all cases, treatment is that of the underlying condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88701462\">",
"    <span class=\"h2\">",
"     Microangiopathic hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Also called fragmentation hemolysis, or thrombotic microangiopathy when accompanied by thrombosis, the hallmark of this condition is the presence of fragmented red cells (schistocytes) on the peripheral blood smear (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Fragmentation hemolysis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The various conditions associated with fragmentation hemolysis are discussed above. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Etiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H19#H19\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88701502\">",
"    <span class=\"h2\">",
"     Causes of intravascular hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravascular hemolysis is associated with red cell destruction occurring in the peripheral circulation, rather than within the monocyte-macrophage system of the liver and spleen. The hallmarks of this condition include increased concentrations of free hemoglobin in the plasma, free hemoglobin in the urine (hemoglobinuria), and the presence of hemosiderin in the urine (hemosiderinuria). Disease conditions associated with intravascular hemolysis due to mechanical causes are discussed above. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Intravascular hemolysis from other forms of mechanical damage'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other conditions that have been associated with intravascular hemolysis (eg, drugs, toxins, systemic disease) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=see_link\">",
"     \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=see_link\">",
"     \"Extrinsic nonimmune hemolytic anemia due to systemic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88701601\">",
"    <span class=\"h2\">",
"     Hypersplenism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersplenism refers to the varying, and usually mild, degrees of anemia, thrombocytopenia, and neutropenia which can be seen in patients with an enlarged spleen. Other than the presence of an enlarged spleen and the occasional finding of teardrop-shaped red cells, there are no distinctive changes associated with this condition. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Extravascular nonimmune hemolysis due to hypersplenism'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/1\">",
"      Marchand A, Galen RS, Van Lente F. The predictive value of serum haptoglobin in hemolytic disease. JAMA 1980; 243:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/2\">",
"      Burns ER, Lou Y, Pathak A. Morphologic diagnosis of thrombotic thrombocytopenic purpura. Am J Hematol 2004; 75:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/3\">",
"      Saigo K, Jiang M, Tanaka C, et al. Usefulness of automatic detection of fragmented red cells using a hematology analyzer for diagnosis of thrombotic microangiopathy. Clin Lab Haematol 2002; 24:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/4\">",
"      Lesesve JF, Salignac S, Lecompte T, Bordigoni P. Automated measurement of schistocytes after bone marrow transplantation. Bone Marrow Transplant 2004; 34:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/5\">",
"      Lesesve JF, Salignac S, Alla F, et al. Comparative evaluation of schistocyte counting by an automated method and by microscopic determination. Am J Clin Pathol 2004; 121:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/6\">",
"      Kim YR, van't Oever R, Landayan M, Bearden J. Automated red blood cell differential analysis on a multi-angle light scatter/fluorescence hematology analyzer. Cytometry B Clin Cytom 2003; 56:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/7\">",
"      BRAIN MC, DACIE JV, HOURIHANE DO. Microangiopathic haemolytic anaemia: the possible role of vascular lesions in pathogenesis. Br J Haematol 1962; 8:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/8\">",
"      Garcia MJ, Vandervoort P, Stewart WJ, et al. Mechanisms of hemolysis with mitral prosthetic regurgitation. Study using transesophageal echocardiography and fluid dynamic simulation. J Am Coll Cardiol 1996; 27:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/9\">",
"      Taylor FB, Coller BS, Chang AC, et al. 7E3 F(ab')2, a monoclonal antibody to the platelet GPIIb/IIIa receptor, protects against microangiopathic hemolytic anemia and microvascular thrombotic renal failure in baboons treated with C4b binding protein and a sublethal infusion of Escherichia coli. Blood 1997; 89:4078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/10\">",
"      Ismeno G, Renzulli A, Carozza A, et al. Intravascular hemolysis after mitral and aortic valve replacement with different types of mechanical prostheses. Int J Cardiol 1999; 69:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/11\">",
"      Baca L, Gibbons RB. The HELLP syndrome: a serious complication of pregnancy with hemolysis, elevated levels of liver enzymes, and low platelet count. Am J Med 1988; 85:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/12\">",
"      Treem WR, Shoup ME, Hale DE, et al. Acute fatty liver of pregnancy, hemolysis, elevated liver enzymes, and low platelets syndrome, and long chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Am J Gastroenterol 1996; 91:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/13\">",
"      Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney Int 1987; 32:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/14\">",
"      Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/15\">",
"      Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/16\">",
"      Lohrmann HP, Adam W, Heymer B, Kubanek B. Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases. Ann Intern Med 1973; 79:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/17\">",
"      Gavras H, Brown WC, Brown JJ, et al. Microangipathic hemolytic anemia and the development of the malignant phase of hypertension. Circ Res 1971; 28:Suppl 2:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/18\">",
"      Khanna A, McCullough PA. Malignant hypertension presenting as hemolysis, thrombocytopenia, and renal failure. Rev Cardiovasc Med 2003; 4:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/19\">",
"      van den Born BJ, Koopmans RP, van Montfrans GA. The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension. Am J Hypertens 2007; 20:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/20\">",
"      van den Born BJ, Honnebier UP, Koopmans RP, van Montfrans GA. Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension 2005; 45:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/21\">",
"      Yeo TC, Freeman WK, Schaff HV, Orszulak TA. Mechanisms of hemolysis after mitral valve repair: assessment by serial echocardiography. J Am Coll Cardiol 1998; 32:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/22\">",
"      Lam BK, Cosgrove DM, Bhudia SK, Gillinov AM. Hemolysis after mitral valve repair: mechanisms and treatment. Ann Thorac Surg 2004; 77:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/23\">",
"      Fishman AD, Hoffman A, Volterra F, et al. Intracaval and intracardiac metastatic nonseminomatous germ cell tumor: a rare cause of hemolytic anemia and thrombocytopenia. Cancer Invest 2002; 20:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/24\">",
"      Kasabach H, Merritt K. Capillary hemangioma with extensive purpura. Am J Dis Child 1940; 59:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/25\">",
"      Blei F. New clinical observations in hemangiomas. Semin Cutan Med Surg 1999; 18:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/26\">",
"      Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Merritt syndrome do not have \"true\" hemangiomas. J Pediatr 1997; 130:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/27\">",
"      Sarkar M, Mulliken JB, Kozakewich HP, et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 1997; 100:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/28\">",
"      Hall GW. Kasabach-Merritt syndrome: pathogenesis and management. Br J Haematol 2001; 112:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/29\">",
"      Blei F, Karp N, Rofsky N, et al. Successful multimodal therapy for kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon: case report and review of the literature. Pediatr Hematol Oncol 1998; 15:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/30\">",
"      Sanyal AJ, Freedman AM, Purdum PP, et al. The hematologic consequences of transjugular intrahepatic portosystemic shunts. Hepatology 1996; 23:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/31\">",
"      Shim D, Wechsler DS, Lloyd TR, Beekman RH 3rd. Hemolysis following coil embolization of a patent ductus arteriosus. Cathet Cardiovasc Diagn 1996; 39:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/32\">",
"      Fisher DC, Sherrill GB, Hussein A, et al. Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer. Bone Marrow Transplant 1996; 18:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/33\">",
"      Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989; 7:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/34\">",
"      Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984; 101:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/35\">",
"      Volcy J, Nzerue CM, Oderinde A, Hewan-Iowe K. Cocaine-induced acute renal failure, hemolysis, and thrombocytopenia mimicking thrombotic thrombocytopenic purpura. Am J Kidney Dis 2000; 35:E3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/36\">",
"      Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/37\">",
"      Frangi&eacute; C, Lefaucheur C, Medioni J, et al. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007; 8:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/38\">",
"      Izzedine H, Brocheriou I, Deray G, Rixe O. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant 2007; 22:1481.",
"     </a>",
"    </li>",
"    <li>",
"     Information available on the FDA website at: www.fda.gov/medwatch/safety/2008/safety08.htm#Avastin (Accessed on July 14, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/40\">",
"      Ross CN, Reuter H, Scott D, Hamilton DV. Microangiopathic haemolytic anaemia and systemic vasculitis. Br J Rheumatol 1996; 35:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/41\">",
"      Asherson RA, Cervera R. Catastrophic antiphospholipid syndrome. Curr Opin Hematol 2000; 7:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/42\">",
"      Uthman I, Godeau B, Taher A, Khamashta M. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev 2008; 22:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/43\">",
"      George JN, Gilcher RO, Smith JW, et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: diagnosis and management. J Clin Apher 1998; 13:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/44\">",
"      Lawrence C, Atac B. Hematologic changes in massive burn injury. Crit Care Med 1992; 20:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/45\">",
"      Abarbanel J, Benet AE, Lask D, Kimche D. Sports hematuria. J Urol 1990; 143:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/46\">",
"      Deitrick RW. Intravascular haemolysis in the recreational runner. Br J Sports Med 1991; 25:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/47\">",
"      Dang CV. Runner's anemia. JAMA 2001; 286:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/48\">",
"      Jordan J, Kiernan W, Merker HJ, et al. Red cell membrane skeletal changes in marathon runners. Int J Sports Med 1998; 19:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/49\">",
"      Telford RD, Sly GJ, Hahn AG, et al. Footstrike is the major cause of hemolysis during running. J Appl Physiol 2003; 94:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/50\">",
"      Miller BJ, Pate RR, Burgess W. Foot impact force and intravascular hemolysis during distance running. Int J Sports Med 1988; 9:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/51\">",
"      Sagov SE. March hemoglobinuria treated with rubber insoles: two case reports. J Am Coll Health Assoc 1970; 19:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/52\">",
"      Blum SF, Sullivan JM, Gardner FH. The exacerbation of hemolysis in paroxysmal nocturnal hemoglobinuria by strenuous exercise. Blood 1967; 30:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/53\">",
"      Banga JP, Pinder JC, Gratzer WB, et al. An erythrocyte membrane-protein anomaly in march haemoglobinuria. Lancet 1979; 2:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/54\">",
"      Bernard JF, Galand C, Boivin P. [March hemoglobinuria. One case with erythrocyte glutathione peroxidase deficiency]. Nouv Presse Med 1975; 4:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/55\">",
"      Platt OS, Lux SE, Nathan DG. Exercise-induced hemolysis in xerocytosis. Erythrocyte dehydration and shear sensitivity. J Clin Invest 1981; 68:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/56\">",
"      Platt OS. Exercise-induced hemolysis in sickle cell anemia: shear sensitivity and erythrocyte dehydration. Blood 1982; 59:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/57\">",
"      Mair DC, Eastlund T, Rosen G, et al. Hemolysis during percutaneous mechanical thrombectomy can mimic a hemolytic transfusion reaction. Transfusion 2005; 45:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/58\">",
"      Wagner HJ, M&uuml;ller-H&uuml;lsbeck S, Pitton MB, et al. Rapid thrombectomy with a hydrodynamic catheter: results from a prospective, multicenter trial. Radiology 1997; 205:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/59\">",
"      Salama A, Hugo F, Heinrich D, et al. Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass. N Engl J Med 1988; 318:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/60\">",
"      Polaschegg HD. Red blood cell damage from extracorporeal circulation in hemodialysis. Semin Dial 2009; 22:524.",
"     </a>",
"    </li>",
"    <li>",
"     Bregman H, Daugirdas JT, Ing TS. Complications during hemodialysis. In: Handbook of Dialysis, Daugirdas JT, Ing TS (Eds), Little Brown, New York 1994. p.149.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/62\">",
"      Mulligan I, Parfrey P, Phillips ME, et al. Acute haemolysis due to concentrated dialysis fluid. Br Med J (Clin Res Ed) 1982; 284:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/63\">",
"      Rosse WF. The spleen as a filter. N Engl J Med 1987; 317:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/64\">",
"      Hasegawa S, Rodgers GP, Shio H, et al. Impaired deformability of Heinz body-forming red cells. Biorheology 1993; 30:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/65\">",
"      HOLZBACH RT, SHIPLEY RA, CLARK RE, CHUDZIK EB. INFLUENCE OF SPLEEN SIZE AND PORTAL PRESSURE ON ERYTHROCYTE SEQUESTRATION. J Clin Invest 1964; 43:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/66\">",
"      Looareesuwan S, Ho M, Wattanagoon Y, et al. Dynamic alteration in splenic function during acute falciparum malaria. N Engl J Med 1987; 317:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/67\">",
"      Looareesuwan S, Merry AH, Phillips RE, et al. Reduced erythrocyte survival following clearance of malarial parasitaemia in Thai patients. Br J Haematol 1987; 67:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/68\">",
"      Ackerman L. Hyperreactive malarial syndrome. J Am Board Fam Pract 1996; 9:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/69\">",
"      Kaneko J, Sugawara Y, Akamatsu N, et al. Spleen volume and platelet number changes after living donor liver transplantation in adults. Hepatogastroenterology 2004; 51:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/62/9194/abstract/70\">",
"      Clavien PA, Camargo CA Jr, Cameron R, et al. Kupffer cell erythrophagocytosis and graft-versus-host hemolysis in liver transplantation. Gastroenterology 1996; 110:1891.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7097 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_62_9194=[""].join("\n");
var outline_f8_62_9194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H88701453\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FRAGMENTATION HEMOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Malignant hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Scleroderma renal crisis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Malfunctioning cardiac valves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Kasabach Merritt syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Insertion of foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Other diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      INTRAVASCULAR HEMOLYSIS FROM OTHER FORMS OF MECHANICAL DAMAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Heat denaturation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Mechanical trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - March hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Thrombectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Cardiopulmonary bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Extracorporeal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Osmotic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      EXTRAVASCULAR NONIMMUNE HEMOLYSIS DUE TO HYPERSPLENISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Splenomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Treatment of hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Kupffer cells and hemolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88701453\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88701462\">",
"      Microangiopathic hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88701502\">",
"      Causes of intravascular hemolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88701601\">",
"      Hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7097\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7097|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/48/12047\" title=\"figure 1\">",
"      Osmotic fragility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7097|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/50/38694\" title=\"picture 1\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/52/4932\" title=\"picture 2\">",
"      Genesis of schistocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/13/22739\" title=\"picture 3\">",
"      Helmet cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/11/23734\" title=\"picture 4\">",
"      Waring blender syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/45/39638\" title=\"picture 5\">",
"      Howell-Jolly bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7097|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/28/8652\" title=\"table 1\">",
"      Major causes of DIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/25/4508\" title=\"table 2\">",
"      Major causes of TTP-HUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/43/27324\" title=\"table 3\">",
"      Causes of splenomegaly",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=related_link\">",
"      Acute complications during hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=related_link\">",
"      Approach to the adult patient with thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=related_link\">",
"      Automated hematology instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15448?source=related_link\">",
"      Complications of transjugular intrahepatic portosystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=related_link\">",
"      Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to systemic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=related_link\">",
"      Hematologic consequences of malignancy: Anemia and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=related_link\">",
"      Pathogenesis and etiology of disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1224?source=related_link\">",
"      Pathogenesis of the hypercoagulable state associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26538?source=related_link\">",
"      Prevention, presentation, and management of saphenous vein graft stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=related_link\">",
"      Scleroderma renal crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=related_link\">",
"      Transfusion reactions caused by chemical and physical agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14583?source=related_link\">",
"      Xerocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_62_9195="Appearance of infected burns";
var content_f8_62_9195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Appearance of infected burns",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organism type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Appearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Staphylococcal infection",
"       </td>",
"       <td>",
"        &nbsp;Previously re-epithelialized areas \"melting away\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudomonas aeruginosa",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Blue-green&nbsp;(pyocyanin), fluorescent yellow-green (pyvoverdine) color and sweet smell",
"         </li>",
"         <li>",
"          Invasive pseudomonas appear purple, punched-out lesions in burns or donor sites",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Candida",
"       </td>",
"       <td>",
"        &nbsp;Small white pustules on the skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes simplex-1",
"       </td>",
"       <td>",
"        &nbsp;Punched-out holes in previously healed skin (2 to 3 mm in diameter)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_62_9195=[""].join("\n");
var outline_f8_62_9195=null;
var title_f8_62_9196="Classification of panniculitis";
var content_f8_62_9196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F65180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F65180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical classification of panniculitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Idiopathic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weber-Christian disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cold, thermal injury, trauma, weight loss, chemical exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Rheumatologic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus (lupus profundus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complement deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other - polymyositis, dermatositis, systemic sclerosis, vasculitis, eosinophilic fascilitis, eosinophilia-myalgia syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignancies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hodgkin's disease and other lymphomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytophagic histiocytic panniculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histiocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Dermatologic diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema nodosum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema induratum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fungal infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis, pancreatitis, amyloid, alpha-1 antitrypsin deficiency, renal failure, poststeroid withdrawal, neonatal pannniculitides, lipoatrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Factitial",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_62_9196=[""].join("\n");
var outline_f8_62_9196=null;
var title_f8_62_9197="Time course thrombotic stroke";
var content_f8_62_9197=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F64107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F64107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stuttering course of thrombotic stroke",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 259px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The course of weakness of the right limb in a patient with a thrombotic stroke reveals fluctuating symptoms, varying between normal and abnormal, progressing in a stepwise or stuttering fashion with some periods of improvement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_62_9197=[""].join("\n");
var outline_f8_62_9197=null;
var title_f8_62_9198="Pregnancy birth and abortion rates in US teenagers";
var content_f8_62_9198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Pregnancy, birth, and abortion rates among US teenagers 15-17 years of age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 363px; background-image: url(data:image/gif;base64,R0lGODlhygFrAeYAAP///wAAAACZZv+ZMwAz/4iIiICZ/8DN//D59szMzEREREBm/zMzMxCfcBEREcDm2f/mzUCzjKDZxv+zZmC/oP/MmYDMs+7u7nd3dzCsg9Ds47u7u93d3fDz/xBA//+mTWCA//+fQCCmef/z5uDm/yBN///582ZmZv/Tpv+/gP/Zs6qqqlVVVSIiIqCz//+5c+Dz7JDTvES0j4ig///s2XDGqdDZ/3CN/0Rp//+sWbDf0DBZ///Gjd3x65Cm/1Bz///kyVC5lv/fwJmZmbDA/2bCo7vk1v/PoP/r1v+nTv+0aSKneojPuJnWwv/WrSJO/zOthf/ChZmt//+tXBGgcFW7mbvJ/93k//+7d8zr4MzW/4CAgEBAQHfJrf/x5GaF/1V3//+gQf/48XeS/39mmf/JkqrdzDNc/xFB/z9MzKq7///du8DAwK95cg858i9G2O749U9Sv59yf++SP79/Zl9Zsm9fpT9f8mBgvyAgIAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADKAWsBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/yvHAwBAmAQVCAggwv9EiokxoIFAA4tViQIkAAAg4ELM2rUxcAhABYYCjAgqGCjyZOyNrQI6CBkSQAFWhjaErCmzZs4c+rcybOnz59AgwodSrSo0aNIkypdyrRp0zymHBQQSfJRAJRYE14lpcDBhYkVL1rNSlbfVlAcDFaEaRCho7Nl/+POg5uLrty77eze0ou37zm+tQD7HRxO8CzDhBNvQxyLseLH1Ry/kgy58jPKrTBb3pxM8yrPnEMPA52KtOjTvUyfUo269d7UrmMrY12KtuzbmWHj3h3M9ijfvIP/1i28OC7goZAbX55J+SfnzKNPgt6JuvTrjaxv0o69+yHuzb2LNwUeU/nx3c9bUo9eOntK79svjy+Jvnzh9iHlv797/1v+AJpHXIAERuJfdgUmqN+ACjaIyIGMQOigZRIqUuGEj134IIYcEqLhdx2G+KEhI4Z4V4kemsghioOwqGJWLgIQ4zoIPGDjjTa+aCCDrWlQQwYCBCnkkEKKEEENOiCg4/+GvLAog5BM9CJDlKI8EAGREWSpZQRAEhlkEBLAsGSKTe4iQxEAGCFAFrxMGQoCNQhJQZKMPKDDj0NmEIOSS8boJJoAUNHElDIs0QMUQaJ5qJBGqIkoFWwWIWQTAMiAqACKXlpFETIIIkMXhAjQxBJFSBpkE01MasQSp2bygAhBUiCmJDDEcGWQDVjAp4p+molmqj1Y2gMAmwLQA6RVQCGIAI0yWymgghShrAydqtlDFZ0K0oMAPWw77CACVFGItJVSKSgAZlBxCZxBivAAJghIAKsAub7Yqy5PtuomAKxOugSlADCrZrRoMkFFkEuUayy3/xIyZRfQLmuEIAYjrPD/tkN+O4kGXdawq6tdumvivbmc6TCVxQ5ShbhZCCwAwduaAUAXCbvpLbaErAppIc7GPHPNoAYKsCUW4KoDKBI0EKTHHZKMi8mD7LtokD1kwSqrzRJcKcI1R+nt1OICAEW2oU68tQBLJJyqqKtaLAnHX37sCbsCiIyh08q0rLElcFBhdioxGG3Kq0FacDePxagZJJWYdKFsKgjcGoHcoyAQRNwO4u3XA0o3EAMrEuAqQYOa4xW4ABlo4ArcddegOoGlnwKDBBZsSYEFErx+DQIUxEr5KvIWSUEMurcXe+USdOnlkBFY8O40MHT5OS06UKA08zWEOd7xoDzQu5DNS3Cj/wW1Xy9kBtkXr4wGnT9/ywPlE9lAEDHM6h7iSM+L+p6KzI4nkRk4EvkGSMDaZUl/daOA+2JxugzYbxcw0EH8imSBBxaHe5pAgAWu1wAKqI8RCJBgBMy3vBIujwK/g9zlBIBCYmggBkEwXxCOZhwMrmuD7eLfumxUwB7q4EaE8F67FqiKpAVpesiQwK3qpiv84A8A8LMA8SYRg+tFYHSyIJwAmJYKKwUpdc2AQQ3Mx0XcWOcENjkBWwJwkLEYInhDylUKDQGDW2WAiLHgHa5klQj4BWFLERieBRuhge/VKxpKbNcHWwOeC7RgCGCxCEYQRAgdzKsBNbBADHFlOEVoEP9XSHzfEq/Ip9mt0IStW2Qh4rVEPlJDi1iUDXhiApORwOQllASA5ThZCB3YUZVwjMAg33dKepFQBMPDkR+HJIL6GeIBthqSK62xSxbehjsccMAKbkkQmRSCJjoRhAbm1cRDGHGLu4rXvERAw1/USnkCiIAzFVE9ZmoJnvub4zSKxkJ9VoY7J3gJVbj5n9OJQJWDqGY8uSQkORpDA/40RLyKKTztfSN0qIuoYrQzkQ0IIpJiecutgqBRKC4xSKT8hjLNwT7UDZNCo1CARwjSFqvQK5SOqFGOxiTOziE0Q6mZJk/XBaQGxJIzNhwqJCIXpKPCtExK5cT3cAqZpEYVEt//owBSn3hVSmBUq0/dxYy689Ww6mKsZI3VP7na1Up8taRYsWpbI2HEDMD1JHKdKyRaatfE5FWvj+DrXTXyV8A6QrCDKaxhCam0vvZFsYtlREsb8FO8sjWylEBAUSu7EchidhGapRdnM+LZz3qyqHhESWlNm4jQCsCpqr0saynxvU7CSLaznUScrHlbqObWE2WNK25/K4ngWta3xO2EcTs73OTSVa0mWa1zE7HchUh3uoiorlaai11IaJcf1+2uOaGrkPCK1xA6UBpYt4vc83ICsf0wr3sLAd99yHe+hGip3czCXfwGdl4tzMd9/ZvQ3R7yHgMm8CC8iLrRqiPBCh7E/zmpCg8IR1gQ1VyvPCx8YUF8Ny/97fBzM7rhEIsYEpwTbTw4fGIAsI7C6WBxizM82G7IuMUAaOBLy3FjHE/Wwd7oMY5DS9l1CHnIm32wiXGc2aLCdhxHZrIeX4uOKDMZAN97MjisfOWsmoPLVz7d5MgB5isbsQGp5UaZr8y6CKQ5G2u+Mt3i+WZrxPnKAIDB9+IJZGfcGc953nOA4bxkQHdCz6DUxp8NLYgHdGnM17BOWmpSgDW28T+MngUO0RxpUaSFA4MA6SQjlGlasE7LfvZ0TRwy0ALgktSlnsWUUc0M8CRAKq7u5kx2Euta8JPWszGFAqZiy1xjutezwCiwkf9hnQIM5NYbELUbkT2L3S7bGNZRSUAwUhA2uiWX1JbF9+p8jEWHexC9K/JlCn3uTyQ51e1t9yuI3GdfmFveunz3Mu6Nb3rXmt34nltR28lsgAe8E0xFZ2cMfvBO7Ha/xeB3wwGQXt9hm+ET5wTdGkDw3mA845xwNEp3fNaPg5wT/DzwLyR+ckHUsV0dF6vJW86JYJL7MDOn+SY0aMWY24LlOk/onkUggRqvJudB5wQMcEgv170m3km3hTqLVIObowLoUX/mnuk1p8YgPeugqJ7+5lf03EAd7LvwEQLBRHJQYB3ti3ghPPVU7/V8He6lqNVJRYAkUrwd7zmVQDHJbnT/cNcF8MsQe56cV527I34VGrAAPptHp0v8/fGZVbyQrL6Iy2PeEv6LQHjO/vkvO770wSY96qF8esuQ4AAGMMACYn+AkbWeMB2A/QI8QIDe+973PyDCim5/lw4Q4QY7+H3vF3ADA7jAACAoge9L4IIOZI74ZIF98n+/AxC4wAaIIMENeE8AD/zAAD44wPNjb4AbLOD97z+/AQ4AfuZ4/h0k8MEPlL+DGxDB+o3QAT4gfcpXgAY4fbNHBCQQHHGGAzOADwdwAwTYeyUAAv9XCTbgA9C3APLHfgfwgR+ogSCwewVofj5Qf7FxXzPge09gBQDggIUAgy/4gJEgg99gAyBA/3699wM+sICuoH6yp4MEUAI3UHuMZHIz8ASCgANggAgyaIOPAIXb4AILMH0WiAsZ+AM6WAIG4IOhoYJKCABn8IAwSABS8AS/JwU4cAa99wWFYIZP8AVf4HtSIAV0uIIE8ARaYA1EMIEgYIS9QAQ56Ht/+IVIyIJk+IAE0IQzuIQ4AABWQABXQAiLWAhfcAaNqAVosIdjwIjSYANVWH4GAIDCQAShSAALAIhVhYRhqAUEoAZl6IKN2IhXIImUKIszgAa9p4QwaIcsKA0dYAC95wGjiAwkAALA54UbxYqC4IpWEItLOAZL+IC1OImDQAAuWItqAABjwIvSqIl7OA0HQP+AP6CMxoiMvXcDpEgYKvh7iQgA2CgIvqiG1GiL1yiLOLCLSjiPeEgAbugMHXADFCh8z0ACoegBPrCMqucX45iO6/gMDTmEBOkXx2MDKFgWAUmBqjgNLkB+qUiRqRF7I/h+BViBG7kREamO2RCM5FeOeOEiNhAAB1h+E0gAO3CSCdEB6FgCOGkNx0iIDylcu9ABAeCBH2iOOOiRPZkPBkB+KvkNBjmMxUgWVsWSy+cC/eACBHiT5HAABzmVsbWQhfCTw+h95vgIrwd7zgeCZymO20d96NCHUhmU1tVfwViTJTB7awmCH7h+skeSM+l7O/B+IMB+hmmUH3iRv+CVUsn/Dlo5l9G1ZDYge4FZmR7wfs0HfyRYmZxpk5rJfi6wlKnAmA75Di6wfcTYlvZlcDZABLGnmfDXgUTwgXRZCCCogYfJfu4Hf0LImTvQg6tgfKcIAqq5DqRJACCgmKsplsTAl365ANu3g9VnCi6wf4RYnO5wnL+JnXOBfbLQAVT4e5dZmOlHm5qQlILZhfuAg9x3gvzFnMgAAfIpn4NAAgYQnZ2ZBnVABvyZBr73fuhHm+oXfdOnngoBntZJgQZaD9lWEwJVU8fmDCOAAi8wABZ6oQOQAymAAhAgCK8ngu8XnW9gB22AoRc6B3IQB24QmB5QiCeBoL/3kfQAHtkkERQh/0nTlgw0AAFCUAE5gKEfMAFC+gEmOgATwAMVMJ/yiQI8MAEm+gEvUAEVkAJEeqF0QAZ4kAZ3gIqzJ5qDQAMUGgIXGgIpMAL1AKO9twNYWWKkMBEc0Gqv1nmtYAIQoAJTKqQ/WqR6mqFiuqcXOgEoYKaFAAEUWqV+aqEh8AIqIKiEQAM8YKgYmgMTkAJSqgLzaQKDMAJC8Kh+GgIocA/iR34l4AO1WWWksBKVZmy09E28hgojoAJUeqiyeqhBOgEVIASYyggjAAF3KqRCSqlCwKiK8KoVIKSzqqeJqgI0MAgQ4KQD8AK5eqZNCZkgRgqONARwmqOiMKF5eqE5EKVJKv+f0boIECCstUCnhCqlL+CrGBoCRyoEiVABiFoB5joPj9l7xMkOZ1Rp2VQA0hahoAABFfqnHOoONOCsRlqv8mCKwOel32AdQ7ASAeAR3XZphtcJKtCtE6AC4/oOAnuhnwqB6DiE02l68CkJKlClIcADChsPI+Cs0JoPx0h+LeqwhHayj9Cs89qx94ACiKoC+iCANfkDLsCddvZxOjsAIVABPJsPNFClH5ACi5oPB0CgwFeyasZwQoCwKdC0qwAEA/AMFQCpUIoCywqqPhCdLaqcR4uzhwABPNCnA1Cmr7AGAxAFggC2j6AERyAIfLsJAwAEn8CrCGuhUXu29pB/E6j/pooWYmD6AnL7AfQaC0qgBGEgBgCgt47wt54QuKPwuHI7AR0qsr6Xmp0GnzTQo4U7AFELr7LgBQOABEngBJk7AFMwAEmABABwBBY6Bbo7AE6QBBjqBH/Lu7b7u7cLvIUAvEkQBcKLu0gQBRfqBcabu6AgBCnwp6N7D0JLiGwLbzKXCDRQrEWaqGZrC0cwBburBLWru1iABUgQuwAQBew7AFjgt30LAHwbv7pLvwAwAH17BEmwvPdLCElQBv8ruEgQBrpbBgUMCiOQvRY6AS27sKcoo9FQOiMwtu1qq8GqC89roV6guQIcvHk7wJ6rv/nLtyacuSgsuC08CJ4rBtJr/6F467lOgKEDPAoRfKE84LXywJ5puqbr1l4mIMFKK7UVXAtgi7n6WwaaOwVRwL8AgAX1K7hPjL9UbMUJDAAxLAg4PACYK8X/uwYAsMC666oD+wHbiw+hSoFE/G/IhQJ9OgGuCwxR8MBOEAZg27tesLu9+7tYnMPAW7yB3MVf3MVekLzNO78ibLx3iwoQUKU/vA9WOYRguXBQlbIT3MbLYQI88LP8AJ4ESIyl6nFNMgF9GgJA6x2TbLitvA/32qJG67asEACGy7TtwclKq8v7wLA7OJGjkRpCgLj3wctLC8TzcAAJ2qLCvHLeCRnILLXKHA/2OYFE+L3HEc2VwcsWmv8DPPDB+WAD4yeYwGnLn4Eh49uthvsCBYsPgsh9N1Ce24zO4mECqlukR6qs9oCmBjiYzQeCNnCUqnB/d0GoLwCpSuvBS6wOubeB+NmZqHh+2hwJuaeW7ncDBu0X+FyscouoUQoB1cwOueeau7kDeXmKJZicjPB6rtl+8DeTC7DRivGqTVqkUXu+GZF7PjCIw6iXhvkDm1mZmEl7McnN0kEDsMrOScyxG4GellnU80fQTBK+poXQH50CnqwQNuCX7Jd+FW0hSN0e42uoH4ACI62QVp1cjrrKdHsaNB0cGau9ohHXwgEBSHzWDf2SY60gIxC33soDWw2S9vxZKjCwf3r/q2kdmYVtWvgcq0AqtcZMlX1tIjbN1GTq1L211kzGq5CLoYq62Phg1wGyzmOaApNdXpXdVRNqqDmg06rd2AqG1+3qziINXqsNWCZw2B+90DzAoaL9F7kdWWCaAkxtuBu61ybL2ROXuhXwAkz9ASz7DqR9VQiNoRsb3Fkr2+EmBIj9rFNrqtx9btwaqeGs3dRQ3ZE1oaub06m9GMMdYfjMA8d9pO/cuON9cp6t0Bm6oYMNDeo9XXT63PytofycwfGdaQOe0CaaqEmK3sz9dKsnCQOuyiaqofd9cfmNekpt3EX6rbf63hsuCmhVagvO36w7qVI6n8p9ywlOc4TapCiO/6xCWgHA7QoBHm47igIV0KRC2ts4zdCl8eITvqt2Ct3le6QVYKm37XZEPuGGoNQ33akqLqVSKyAjDuWksKtSyq57WgFYHuFaHgxcLqU23uJiPQoYgEsV+22wNuY89hsB8BL/erFwvmWkoKrFFqdpfuesNwqqKlDeRAjglBN+TmZ5LlB7rq2HHmSJ/lE3GlJ23ujwTeI1AWptzuiUXulivunYkOOebnlPHupHl+WkDgygfurTMeqqPhym3uqv7gklDuthXnK0frqdfuvga+u6nt6s3uuckOrA3ue8PuwA/uvGXuuHl+zHHuvMDgvC/uxkkuvSTgzRXu0yguzYviPOvv/tBa3t3g6w9Rzu5Qbu5C6nqJDp4n7uqGwKdf7m7D7Mp5Ct6x7v9pbugr5rTrHv/N7v/v7vAB/wAj/wBF/wAZHui17vQ37v0Mzw5k4b6vHu6D4ZDe/w3d54Bsce6j7pC2/ugjBWIG/xlfBnIV/xFx/sIg8fuV3yKb/sDz961E4eJn/y2zHzLm93NA/vMU8LLJ/zyq7yPk/sO49zLT/uQz/xxd4KXPALS8/0Tu8LTc8LUY/zR2/vgeHxVj/tSZ/14D7rWS9kaz4IFVsR2iYQgqAAAaFGqRD2NMVGZC+xAzFpAVFpqMD2lvb2AeAAQ3D2aa8Kdj/2AKBtev8QNkH3pZD/AAARAGq/AQ4QAC1QEf8QEHsPAGiv+KiA+H0f+I3/+A+R+Hsv9wFg+EJv9JZO5zdKFWKxAgHwpi1wATV6dXMO6RWB+gOh+hzwaZ8R+wAQSVQhFYEfABcQE66vTbBv+rM/Er6/AcCP+6kwBM92o76PASPREACg+sHf+q9vCs6/+9BfadL/EQ5h/cyv8Dw/7y+h+hUxERdwAgyQACpxASBx9qJfCsaG/ty//u3//nI/U+YPCAAAKwEJAAkBFwEFgg4rLBiCCoyClZaXmJmalwUKgoSGiIqUjhwBpyybqqusAIoJogAbAQCOggEbkJKUrb2tr7GztSu3G6aovbS+y8ys/8rN0J2VLKcOiRsMJ4sAk5In0OCC0oLUAdYX2Nq8hw7r4cvjAOXnBdUBK93c3+/N8fOJ9czdq5SgHT9oCiIJkxXA1IZbQ/Ip2HdwWUKGgmY5hEjQoLOKIFU9C7kpXqUCDoa5cqSLmzuSmkyKS2nrgq1K+WCqkgkApSVECVrm1BnTE6eUBAtZGkr00oVsgoLRuolL6Mumgp7uk6oSAK6lVzGNxHpwLFmZGww6iFRwRYEWFzjcJMvJaKW0jNayc8vWwUO6dS/hrcSBgae3cecCFmc3o0cAhQ/3/bs47RBLBjEwkJeK0AXEcoktluXgcqXMm1l0Bji5ldnRzF4TPXWKA/8AbdtIn4rE7RTF0bQb3j5FKe1uWS2Ow/ZK2zZuSkNQXZDkeznz2sNzRw/AYvqG5AF4j8Zd3XgLQ4VPmVZQHTb5AN/Mo2egHrnyj9ahyc7Pv7///wAGKCA/+w14i4EIJqjgggw2GJuDlRQI4YQUVmjhhctIOKCGGHbo4YcgBsihiCGWaOKJKNI1IoArpujiizCi2KJ/M8Zo4404Mlgjf2zk6OOPQDbYY5BEFmnkkUgmqeSSTDbp5JNQRtkLBnYFxIAh4NWHzSlSdumlhQnQB584pzAwXXoBXPbeb2SdYhRQPW2WFAemsPnlnXgaOARbhcDJQCSqDZJIJRe0YNpi44DBcsig3gBAZZ6QRmrgKwXIKQ1VlL21nD/2TDeIA7YpYE0ADNgm6amoLnbROJp+5ZVpoW3a2EyVtEAJC5RAlequvIKklTiWeoKpICfMChhaHqHkaaXT/dnrs9AyY1lShjgbqGeLUrZYcM4Rl9Vj8rjpabTklovJmj2VeaaY66Vi7rvwxivvvPTWa++9+Oar77789uvvvwAHLPDABBds8MEIJ6zwwgw37PDDEEcs8cQUV2zxxRhnrPHGHHfs8ccgh/xiIAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rates per 1000 women between 15 and 17 years of age.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Ventura, SA, Abma, JC, Mosher, WD, et al. Estimated pregnancy rates for the United States, 1990-2005: an update. National vital statistics reports; vol 58 no 4. Hyattsville, MD: National Center for Health Statistics. 2009. Accessed at",
"     <a href=\"file://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_04.pdf\">",
"      file://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_04.pdf",
"     </a>",
"     . (Accessed on September 20, 2010).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_62_9198=[""].join("\n");
var outline_f8_62_9198=null;
var title_f8_62_9199="Standard cricothyrotomy step seven";
var content_f8_62_9199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Standard cricothyrotomy step seven",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <font class=\"red\">",
"     <font color=\"black\">",
"      Remove the obturator.",
"     </font>",
"    </font>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Custalow CB. Color Atlas of Emergency Department Procedures, Elsevier Saunders, Philadelphia 2005. Copyright &copy;2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_62_9199=[""].join("\n");
var outline_f8_62_9199=null;
